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Abstract
The Pulmonary route has been traditionally used to treat diseases of the
respiratory tract. However, important research within the last two decades have
shown that in addition to treating local diseases, a wide range of systemic diseases
can be treated by delivering drugs to the lungs. The recent FDA approval to market
Exubera®, an inhalable form of insulin developed by Pfizer, to treat Diabetes, may
just be the stepping stone that the pharmaceutical industry needs to market other
drugs to treat systemic diseases via the lungs. However, this technology still needs
repeated drug doses to control glucose levels, as the inhaled drug is cleared rapidly.
Technologies have been developed where inhaled particles are capable of
controlled release of drug from the lungs. An important feature of these technologies
is the large geometric size of the particles that makes it difficult for the lung
macrophages to clear these particles, which results in longer residence times for the
particles in the lungs. Owing to the porosity, these particles have lower densities
making them deliverable to the deep lungs. However, no modulation of drug release
can be achieved with these technologies when more drug release may be required.
This additional requirement can only be assuaged by additional dosing of the drug
formulation, which can have undesirable effects due to excess loading of excipients
in the lungs.
In an attempt to bring about modulation of release from long residence time
particles, a novel concept was developed in our laboratory that has been termed as
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the Agglomerated Vesicle Technology (AVT). Liposomes with encapsulated drug
were agglomerated using well known cross linking chemistries to form
agglomerates in the micron sized range. The large particles exhibited aerodynamic
sizes in the respirable size range with minimal damage to the particles upon
nebulization. By breaking the cross links between the liposomes with a cleaving
agent, it was anticipated that triggered release of drug from the AVT particles could
be achieved. In vivo studies done in healthy rabbits showed that post-administration
modulation of drug release is possible from the AVT particles after the introduction
of the cleaving agent.
This study has important implications for the future development of this
technology, where the AVT particles can be made “sensitive” to the product of
disease. It is envisaged that a single dose of AVT containing the appropriate drug
when administered to the lungs would maintain drug levels at a controlled rate over
an extended period of time. When the need for more drug arises, the product of the
disease would trigger the AVT particles to release more drug as needed to control
the condition, thus eliminating the need for repeated drug doses and improved
compliance amongst patients.
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Chapter 1
Introduction
1.1.

Pulmonary route of drug delivery
Inhalation therapy has been used for more than 4000 years primarily for

the treatment of respiratory diseases. Ancient therapies have included inhaling
smoke emanating from lit medicinal concoctions to inhaling vapors released
from aromatic plants [1]. Aerosolized delivery of drugs to the lungs has greatly
improved the treatment of various respiratory diseases. As examples, antiinflammatory and bronchodilator aerosol medications have been the cornerstone
of asthma treatment; and antibiotics have been used for treating cystic fibrosis
and lung infections.
The pulmonary drug delivery area has grown tremendously since the
mid 20th century into a multi-billion dollar industry. During the past two
decades, the lungs have been considered a promising route for the
administration of therapeutics not only for the treatment of local pulmonary
diseases (e.g. asthma) but also for the treatment of systemic conditions (e.g.
diabetes). This increased interest in pulmonary drug delivery is based on (1) the
high bioavailability of protein and peptide drugs when delivered to the
respiratory system, (2) the large surface area (140 m2) of the adult lung, in
intimate contact with the circulatory system via the alveoli, (3) the equivalence of
inhalation to arterial injection, and (4) the consequent avoidance of first pass
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hepatic and renal effects. Compounds with high potential for delivery by the
respiratory route include insulin, cyclosporine, interferon, antitrypsin, protease
inhibitors, deoxyribonucleases, recombinant adenoviruses and many more [2].
Further, in the wake of recent terrorist attacks on the United States, there has
been a renewed interest in protection against biological agents, many of which
infect via the respiratory route, and are therefore best protected against by the
respiratory delivery of anti-infectives and antibiotics [3].
It has long been recognized that the lung allows high systemic
bioavailability of proteins like insulin [4]. This has driven the development of a
number of inhaled insulin projects [5]. The goal for a systemically active, inhaled
drug is to reach the deep lung region in order to be transported into the blood
stream. In order to reach the deep lung, particles must have an aerodynamic
diameter (Daer) in the 1 – 5 µm range. The aerodynamic diameter is related to the
geometric diameter (Dgeo) as Daer=Dgeo·ρ0.5, where ρ is the specific gravity of the
particle. For particles with specific gravity = 1 (the case for most solid
pharmaceutical powders), the geometric diameter and the aerodynamic diameter
are identical. Therefore, particles that are optimal for deep lung delivery will
often also have a geometric diameters in the 1 – 5 µm range, putting them in the
size range where pulmonary macrophage activity is the highest (this is not
surprising, since the macrophage system was probably optimized by
evolutionary processes to eliminate inhaled particles that reach the deep lung).
Solid drug particles optimized for drug delivery to the deep lung would
2

therefore meet the same fate, and be cleared by macrophage uptake and likely
pass via the pores of Kohn into the circulatory system and thence to the
reticuloendothelial system (RES). Only the portion of the particles that were not
thus affected would contribute to drug delivery. A secondary consequence of
this rapid macrophage uptake and clearance is the short duration of delivery for
an inhaled drug, since the delivery must take place before macrophage mediated
clearance of the particles takes place. Typically, this time frame is around an
hour.
However, a breakthrough discovery was made around 1997, when
Edwards et al. [6] recognized that the macrophage uptake system relies on the
geometric diameter of particles to recognize and clear them, while the deposition
of the particles in the lung depends on the aerodynamic diameter of the particles.
They fabricated light, porous particles that were physically quite large (10’s of
microns) but had the aerodynamic behavior of smaller (1-3 microns) particles.
These porous particles, originally fabricated from PLA/PLGA polymers loaded
with insulin were shown to reside in the rat lung for extended periods of time,
and provide extended release of insulin for up to 72 hours.

1.2.

Proposed research aims
While these advances permit controlled release of the drug at some pre-

programmed rate, they do not permit modulation of this rate on demand. To
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address this need, our group has advanced a new technology [7] based on
chemically agglomerated vesicles (the AVT technology) that allows the
modulation of the release rate from long-residence time particles deposited in the
lung. The AVT particles exhibited controlled release patterns of the antibiotic
Ciprofloxacin in vitro. The modulation was accomplished by cleavage of the
linkages agglomerating the vesicles, both disrupting the vesicular structure and
releasing internal surface area for transport of the drug across the vesicle wall.
However, the cleaving agents used to trigger the release from the first generation
of AVT particles are not acceptable for in vivo applications. Therefore, a new
generation of in vivo compatible agglomerated liposomes was recently
developed based on PEG conjugate containing a dithiobenzyl (DTB) urethane
linkage cleavable by cysteine. It has been shown in vitro that the release rate of
encapsulated compounds from these carriers can be modulated by the addition
of mild thiolytic agents such as cysteine [8]. While there are low levels of cysteine
and glutathione in the lung, capable of causing some cleavage of disulfide links
between nanoparticles, the further addition of a free thiol as a “cleaver” dose
would trigger the accelerated release of drug by cleavage of the inter-particle
links and liberation of free nanoparticles. When administered in vivo, these
particles facilitated post-administration-modulation of drug release. Thus,
insulin release with the possibility of controlled post-administration changes in
the release rate was demonstrated for the first time [9]. However, continuing
concerns about the cleavage of this linkage by endogenous cysteine remained.
4

This therefore led us to seek alternative linkages that would not cleave in the
presence of endogenous thiols, but would cleave upon the administration of
exogenous cysteine, at levels higher than that present normally in the body. The
availability of such a linkage would facilitate more complete control over the
release of drug from the nanostructured AVT particles.
In this study, it is sought to extend the application of the AVT platform
and demonstrate in a healthy animal model the controlled and cysteine-mediated
modulation of drug release from agglomerates in the lungs. As a test drug,
Ciprofloxacin has been used in this study.
The following specific aims were addressed to test the controlled and
modulated drug release features of the Agglomerated Vesicle Technology (AVT):
1)

In vitro characterization of the agglomerates based on size/structure
(utilizing light scattering and microscopy techniques), and release
characteristics to select the optimal conditions for making the AVT to
be tested in vivo.

2)

To test in a rabbit model the controlled and modulated release
characteristics of different AVT and liposomal formulations of
Ciprofloxacin after instillation in the lungs.

3)

To evaluate acute toxicity issues of the AVT by instilling Ciprofloxacin
formulation of AVT and liposomes in the lungs of rats and evaluate
inflammation by histology and assay of cytokines.

5

Chapter 2
Background and Significance
2.1.

Respiratory tract physiology
The success of a therapy using aerosolized medications depends on its

ability to deliver sufficient drug to appropriate sites in the lungs with minimal
side effects. This in turn depends on aspects of airway anatomy and physiology,
which change with disease and age [10, 11].
The respiratory tree includes (1) the conducting airways with thick walls
consisting of the trachea, the 2 bronchi and the bronchioles, and (2) the alveoli
(where gas exchange occurs) across thin walls. The trachea is a flexible tube
extending from the larynx. It is composed of 3 layers as shown in figure 1a: 1) the
mucosa made up of goblet cells and ciliated epithelium, 2) the submucosa which
is a connective tissue, and 3) the adventitia, which is the outermost layer made of
C-shaped rings of hyaline cartilage. The trachea bifurcates into the left and right
bronchi which continue subdividing into the bronchioles (figure 1b). The tissue
walls of the bronchi and the bronchioles mimic that of the trachea. However, as
the conducting airways become smaller, structural changes occur. There is a lack
of cartilage support and increased amount of smooth muscle. Additionally, the
epithelium is cuboidal without mucus-producing cells. The respiratory zone is
defined by the presence of alveoli. The terminal bronchioles feed into the

6

respiratory bronchioles which lead in to alveolar ducts, then to terminal clusters
or alveolar sacs composed of alveoli. The respiratory zone accounts for most of
the lung’s volume since it consists of 300 million alveoli providing a tremendous
surface area for gas exchange.

(a)

(b)

Figure 1. (a) The wall of the trachea and (b) the upper respiratory tract consisting of
the trachea, the bronchi and the bronchioles [12]

The airways bifurcate more than 17 times resulting in an enormous
surface area of the alveolar region. A laborious study conducted by Weibel [13]
extracted the dimensions in different regions of the lungs summarized in figure
2a. In many recent studies, the alveolar surface area of human adults was
estimated to be ~100 m2 [14, 15], which represents half a tennis court. The total
lung capacity averages 6.7 and 4.9 liters in men and women, respectively [15]. It
7

should be noted that under normal (tidal) breathing conditions the lungs are half
empty. The conducting zone contains 4% of the inhaled air, and the alveoli the
rest.
A drug molecule administered to the lungs must overcome 5 barriers in
order to reach blood circulation [16]:
1.

Surfactant: The lung surfactant spreads at the air/water interface. It is a
single molecule thick in most places with the fatty acid tails facing the air
side but it may cause large molecules to aggregate which could enhance
engulfment and digestion by airspace macrophages. The surfactant’s role
is to reduce the surface tension of the alveolar walls in order to prevent
the complete collapse of the airways during exhalation.

2.

Surface lining fluid: It is the reservoir for lung surfactant. It has similar
composition as plasma. In the airways the thickness of the lining fluid is
between 5-10 μm, and in the alveoli 0.05-0.2 μm. The fluid in the
conductive airways contains mucus which flows toward the trachea by
the action of cilia. Mucus is absent in the alveolar fluid.

3.

Epithelium: This is the most important barrier. It consists of a single-cell
layer of thick columnar cells in the airways, and thin and broad cells in the
alveoli.

8

(a)

(b)

Figure 2. (a) Characteristic dimensions of the airway tree [13] and (b) Epithelial cell
size and surface fluid thickness in different regions [16].

4.

Interstitium and basement membrane: The interstitium is the extracellular
space inside tissues. The epithelial and endothelial cells are attached to a
tough but thin layer of fibrous material known as the basement
membrane. Its role in macromolecule absorption is not known exactly.

5.

Vascular endothelium: The final barrier to systemic absorption is a
monolayer of cells that construct the walls of small blood vessels and
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lymphatics. Even at the tightest junctions, the vascular endothelium
exhibits higher permeability to macromolecules than the epithelium.

2.1.1.

Deposition and clearance of inhaled particles
For efficient pulmonary drug delivery, the aerosol must deposit in the

lower airways. Since the lungs are in direct contact with the atmosphere,
different defense lines protect the deep lungs from exposure to particles present
in the inhaled air. There are several mechanisms in the upper respiratory tract
that remove particles and reduce deposition in the lower airways. These
mechanisms include impaction, sedimentation and diffusion (related to
Brownian motion) [17, 18]. Small particles of diameters below 1 μm remain
suspended in the air and are exhaled. A small fraction of them reaches the deep
lungs and deposit due to Brownian motion. Particles with diameters larger than
5 μm deposit in the upper respiratory system (mouth, throat and
tracheobronchial airways) due to inertial impaction. Insoluble particles are
cleared rapidly by cilia within the mucus layer lining the epithelium, which carry
particles to the pharynx where they are swallowed, whereas soluble particles are
removed via the lymphatic system. Particles with diameters of 1-5 μm deposit in
the deep lungs due to a combination of inertial impaction and sedimentation.
Scavenging cells (primarily macrophages) engulf and clear these particles either
by the mucociliary elevator or the lymphatic system.
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Deposition in the respiratory tract is affected by the aerosol’s particle size,
the patient’s inhalation technique and health, and the aerosol delivery system
[19]. The most important formulation variable for respiratory drug delivery is the
aerodynamic diameter (Daer) of the particles. The mass mean aerodynamic
diameter (MMAD) for non-porous particles is defined by:

MMAD=

ρ
⋅D
ρ1

where, D is the mass mean geometrical diameter of the particle, ρ is the
mean particle mass density, and ρl = 1 g/cm3 (density of water). The MMAD of
the particle corresponds to the diameter of a sphere of ρ = 1 g/cm3 were it to fall
under gravity with the same velocity as the particle in question. It is possible to

Phagocytosis rate

Cleared by
mucociliary elevator
Cleared via lymphatics

~1-5 µ

0

Particle Geometric Diameter

< 1 µm

1-5 µm

Not cleared

20µ
> 10 µm

Exhaled
Deposit in the deep lungs
Figure 3.

Deposition/clearance fate of inhaled particles in/from the deep lung
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generalize the above equation for highly porous particles. Experiments show this
optimal aerodynamic diameter to be in the range of 1-5 μm [17]. However, the
highly active pulmonary macrophage system is optimized to clear these particles
arriving at the deep lung. The majority of crystallized pharmaceutical powders
with specific gravity close to 1 and aerodynamic diameters in the respirable
range are subject to rapid macrophage uptake, clearance, and removal. The
expected lifetime of particles in the 1-5 µm range in the lung is therefore less than
1 hr. Figure 3 summarizes the defense mechanisms of the lungs in order to
quickly and effectively remove inhaled particles.
A breakthrough discovery came in the mid 1990s, when Edwards et al. [6]
recognized that the macrophage uptake system relied on the geometric diameter
of particles to recognize and clear them, while the deposition of the particles in
the lung depended on the aerodynamic diameter. They demonstrated that by
preparing particles with very low specific gravity (<0.1), aerodynamic diameters
in the respirable range (1-5 μm) could be achieved with geometric diameters in
the 30 µm range. These geometrically large particles were too large for
macrophage uptake and therefore provided long residence time in the lung.
Controlled release of insulin over several days was demonstrated by this
technique. This technology (called AIR®) has led to clinical development of an
inhaled insulin formulation by Alkermes and Eli Lilly Company.
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2.2.

Agglomerated Vesicle Technology (AVT)
In an attempt to bring post-inhalation modulation of drug release rate, our

group has recently proposed a microparticle agglomerate of nano-sized
liposomal particles, with the agglomeration process consisting of chemical crosslinks that are capable of cleavage. This approach has been named as – the

(a)

(b)
Cross-Linking
Chemistry

(c)

in-vivo cleavage

+

Figure 4.
Schematic of core particles bearing ligands (a); agglomeration of core
particles by linkers to form agglomerates (b); based on the linker chemistry some can
be cleaved in-vivo by components of lung fluid or addition of a second agent (c).

Agglomerated Vesicle Technology (AVT) since it is based on the controlled
agglomeration of particles. The cleavage of the cross links releases internal
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surface area, as well as possibly results in the disruption of the bilayer. The result
is a rapid release of encapsulated drug upon contact of the agglomerates with the
cleaving agent. The approach is illustrated in Figure 4. In this figure, core
particles with spacer arms, bearing ligands on their ends are shown as the
starting point. The core particles could be polymeric nanoparticles with drug
incorporated into them, or even drug nanoparticles to which the spacer arms
have been conjugated. A particularly versatile choice for core nanoparticles are
liposomes, that can conveniently be fabricated to present a variety of ligands at
the distal ends of spacer PEG chains [20]. The ligands at the distal ends of the
spacer arms are then used to cross-link the nanoparticles into larger clusters or
agglomerates, by using a suitable chemical reaction. For example, by choosing
nanoparticles with –COOH and –NH2 ligands, one could cross-link them using
the carbodiimide reaction [21]. Depending on the conditions of the reaction
mixture, one would expect the resultant agglomerates to have different densities.
For example, under diffusion-limited conditions, where the overall concentration
of the core nanoparticles and linker are low, the so-called diffusion-limitedaggregation condition would apply, resulting in a limiting fractal dimension of
1.5-2.5 [22 - 25]. Depending on the particular conditions of the chosen reaction
scheme, other fractal dimensions could be achieved. Most chemical reactions are
expected to be rapid compared to the diffusion of relatively large (100 – 400 nm)
liposomes, resulting in DLA (diffusion limited agglomerate) clusters being
formed.
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Zasadzinski has shown that colloidal aggregation can be made selflimiting by controlling the ratio of the reactive groups on the colloidal surface to
cross-linking agents [26]. According to that study, unilamellar vesicles (0.1 μm)
incorporating a small fraction of receptors formed aggregates via ligand-receptor
interactions. The aggregates had dramatically different sizes depending on the
ratio of receptors to cross-linking agents. However, the streptavidin-biotin based
linkage is likely to be immunogenic and therefore is not acceptable for clinical
use.
The choice of the linker can impart other interesting properties to the
agglomerates. For example, EGS [ethylene glycobis(succinimidylsuccinate)] links
amino groups with each other, via an ester linkage [21]. The ester bond can be
readily hydrolyzed with hydroxylamine, resulting in breakage of a link between
the core nanoparticles. If an aggregate were built using the EGS linker, one
would expect cleavage of the links to slowly result in release of the core
nanoparticles. Assuming that the nanoparticles release drug much faster than the
agglomerates, one would therefore expect a progressive increase in drug release
rate as the hydrolysis of linkers proceeded. Similarly, if one were to cross-link
particles using a dithiobenzyl (DTB) urethane linkage [27], the linker would
carry a disulfide bond that would be cleaved by the addition of free thiols. While
there are low levels of cysteine and glutathione in the lung, capable of causing
some cleavage of disulfide links between nanoparticles, the further addition of a
free thiol as a “cleaver” dose would trigger the accelerated release of drug by
15

cleavage of the inter-particle links and liberation of the free nanoparticles. A nonbiocompatible cleaver can be used as an in-vitro tool to investigate the release
profile.
Other very interesting structures are also conceivable, for example initial
agglomeration by a non-cleavable linker, followed by agglomeration with a
cleavable linker, or initial agglomeration by a cleavable linker followed by
additional agglomeration by a non-cleavable linker. Inducing cleavage in such a
structure would result in other triggered release patterns that could potentially
be therapeutically useful.

2.2.1.

Agglomeration methodology of liposomes
While one could conceive of any nanoparticle presenting an appropriate

ligand on the external surface as a candidate for this technology, we have
focused on the use of liposomes. Liposomes have several advantages for use as
the core nanoparticles: (1) they can easily be produced in a range of sizes, (2) they
can efficiently be loaded with a variety of drugs, (3) they can easily incorporate
polymer spacers on their exterior surfaces by anchoring the spacer to a lipid
molecule that in turn resides in the bilayer wall, (4) the bilayer wall composition
can be manipulated to achieve a range of drug release properties, and (5) many
lipids, including the ones chosen for liposome preparation are already
abundantly present in lung surfactant and lung fluids, and would therefore be
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well tolerated by the lung, making high excipient loads quite acceptable. One
would have to consider the toxicity of the lipid-polymer conjugate used to
provide the inter-particle spacers, but that problem appears small compared to a
situation where the entire particle is composed of a polymer that has toxicity
issues. In this work therefore, liposomes were chosen that consisted of 55-58%
DPPC bilayer, with 40% Cholesterol and 2-5% DSPE-PEG-NH2.

Figure 5. a) A unilamellar liposome; and b) details of the lipid bilayer.
Liposomes, or lipid vesicles, are self-assembled colloidal particles (figure
5) that occur naturally and can be prepared artificially, as shown by Bangham in
the mid-1960s [28, 29, 30]. Initially, liposomes served as a case to study biological
membranes and later in the 1970s they were considered candidates for drug
17

delivery. Presently, liposomes are the leading nanoparticles used in drug
delivery with several products based on them. These products range from drugdosage

forms

(antifungals,

anticancer

agents,

vaccines)

and

cosmetic

formulations (skin-care products, shampoos) to diagnostics and various uses in
the food industry.
The benefits associated with the encapsulation of drugs in these carriers
were mainly two-fold: (1) protection of the drug from chemical or metabolic
degradation after administration, and (2) reduced toxicity through decreased
exposure of the drug to healthy tissues. In general, these preparations exhibited
significant reduced toxicity in comparison to the same drug administered by the
conventional, unencapsulated form. A classic example is that of the antifungal
drug, Amphotericin B, which reacts with all cells resulting in high toxicity. Also
the peculiar solubility issues of the drug make it an ideal candidate for liposome
encapsulation. Early studies in laboratory animals using liposomes containing
Amphotericin B showed an increased therapeutic index [30].
A further reason for selecting liposomes as the parent nanoparticles in the
agglomerated particle technology is the wealth of literature on the use of
liposomes for respiratory drug delivery. Liposomes have long been considered
as respiratory drug carriers in aqueous nebulizer-based formulations. A concern
with such use, of course, is the disruption of liposomes by the high shear forces
experienced by the fluid in the nebulization process. However, there have been
studies [31] examining the effects of nebulization by different nebulizers on the
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encapsulation of drugs by liposomes. Based on this, one would then be able to
select a nebulizer that minimizes the disruption of liposomes, and the resultant
loss of encapsulation. Liposomes have also been considered as candidates for dry
powder inhalation. While liposomes are in general not stable upon drying (the
existence of the bilayer depends on the free energy reduction achieved by the
assembly of the amphipathic molecules in aqueous medium) there have been
numerous examples of the drying of liposomes after protecting the bilayer with a
suitable sugar such as trehalose [32]. Liposomes and even simple lipids have also
been shown to promote trans-alveolar permeation of drugs. For example, it has
been shown by Mitra et al. [33] that the mere presence of lipids co-administered
to the lung along with insulin increased the bioavailability of insulin by 40%.
Similar enhancements have also been reported by the same group for liposomes
containing insulin. It therefore appears that liposomes are a good choice for core
nanoparticles.

2.2.1.1.

Preparation of liposomes
Factors that influence the hydration of the lipids and the vesicle formation

process are the size of the raw lipid material, the hydration temperature and the
bilayer phase transition temperature, shear forces, composition of the hydration
medium and time [30]. Vesicle formation is greatly accelerated when the
hydrated lipids are in the liquid crystalline state above their main transition
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temperature (Tm). The vesicles formed are predominantly multilamellar vesicles
(MLVs). When a drug is dispersed with the dry phospholipids or in the
hydration buffer, encapsulation will occur during the vesicle formation.
The hydration of the lipids using organic solvents is achieved by injecting
an organic solution containing the lipids, which is miscible with water (e.g.
ethanol), into an aqueous phase. The resulting dilution of the organic solvent
induces MLV vesicle formation. An attractive sizing technique to obtain small,
unilamellar vesicles is low-pressure extrusion of the liposomal suspension under
moderate pressures (<1 MPa) through polycarbonate membranes with welldefined pore diameters. Polycarbonate filters with pore sizes ranging from 0.8
down to 0.03 μm are available. The resulting vesicle size and lamellarity are
related with the pore size, although effects of the medium and phospholipid
composition are generally observed as well. Extrusion rates depend on the
bilayer phase. The highest rates are obtained with phospholipids heated above
the Tm, even when cholesterol is present, which abolishes the transition from the
gel to the liquid crystalline state. The possible effects of the phospholipid
composition on the obtained vesicle size can be minimized by repeated extrusion
cycles.
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2.2.1.2.

Encapsulating drugs within liposomes
Drugs can be encapsulated within liposomes by two different ways: (1)

passive encapsulation, where the drug is entrapped within the liposomes during
the vesicle formation process, and (2) active or remote loading, where the drug is
loaded into preformed vesicles.
Passive encapsulation is suitable for water soluble compounds that do not
interact with the bilayer. The encapsulation efficiency directly depends on the

mg of encapsulated insulin / mL of liposomes
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Figure 6.
Dependence of the amount of encapsulated insulin to size of liposomes
passively encapsulating insulin from a pool concentration of 30 mg/mL.
aqueous volume enclosed by the vesicles, which itself depends on the
phospholipid composition of the dispersion and the lamellarity and morphology
of the vesicles. The encapsulation capacity but not the efficiency can be improved
by using a high drug concentration (limited by solubility) during the vesicle
formation process. The physical dimensions of lipid molecules and their
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contribution to the encapsulation efficiency of liposomes has been described by
Lasic [30].
Using insulin as an example, figure 6 shows the portion of a 30 mg/mL
pool insulin concentration loaded passively into liposomes as a function of
liposome size, and lipid concentration. Assuming a bioavailability of 25% of
inhaled insulin [5] and a daily dose of insulin for an adult Type-I diabetic patient
of 50 IU (1 mg≈27.6 IU), one can readily see that, in the case of 250 nm
liposomes with 75 mM lipid content and 30 mg/mL insulin pool concentration,
about 0.650 ml of suspension and 35 mg of lipid will be needed to carry the
insulin required. While with a polymeric excipient, this load may be
unacceptable, with a lipid excipient, one can easily justify this drug:excipient
ratio, since the lipids used are already present in the lung in larger quantities
than administered with this formulation.
The remote loading depends on a proton gradient along the liposomal
bilayer. Partition coefficients of drugs can depend on the pH, and to a lesser
extent on the ionic strength of the aqueous medium [28]. 100% of the drug can be
effectively encapsulated within liposomes depending on the conditions selected.
The earliest drugs characterized for active loading were lipophilic cations or
anions [34]. It has been shown by a number of groups [35 – 37] that a zwitterionic
drug like Ciprofloxacin can also be actively loaded using an ammonium sulfate
ion gradient method. Ciprofloxacin possesses both an amino and a carboxyl
functional group. At a pH < 6 it has a net positive charge, whereas above pH 9 it
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has a net negative charge. Below or above these pH extremes, Ciprofloxacin is
highly soluble in aqueous media, however at physiological pH values it is
practically insoluble. In general, a charged species cannot cross the bilayer at a
significant rate; consequently it is the uncharged species that is able to diffuse
into the vesicle down its concentration gradient.
In a two chamber aqueous system separated by a membrane as illustrated
in figure 7 using doxorubicin as an example, accumulation will occur at the low
pH side under dynamic equilibrium conditions. A transmembrane pH-gradient
causes accumulation of doxorubicin (pKa=8.1) in the low pH interior. In the
unprotonated form, doxorubicin can diffuse through the bilayer. At the low pHside

the

molecules

are

predominantly

protonated,

which

lowers

the

concentration of this drug in the unprotonated form, and thus promotes the
diffusion of doxorubicin to the low-pH side of the bilayer from the external side.

INSIDE

(NH4)2SO4

OUTSIDE

2NH4+ + SO422H+ + 2NH3

NH3

drug-H+
drug

drug + H+

liposomal wall

Figure 7. Schematic representation of the active loading technique.
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drug-H+

2.2.1.3.

Tether selection for agglomeration
The density and porosity of the agglomerates are clearly a function of the

spacer length chosen and the size of the starting particles. Further, the more rigid
this spacer is, the more rigid the agglomerate will be. However, a rigid, nonflexible spacer would limit the efficiency of agglomerate formation since the
terminal ligands, constituting the reactive groups that help the nanoparticles
agglomerate, would not be free to move in all directions and seek other reactive
groups during the reaction step. The reaction rate would therefore be limited by
the diffusion of the relatively large, slow moving liposomes. It is not clear at this
time, what the ideal choice of spacer for any given application would be, and the
effect of different tethers is a topic of ongoing investigation. In the present work,
polyethylene-glycol (PEG) tethers were chosen since: (1) they are readily
available conjugated to lipids and (2) much is known about the safety of PEGlipids.
2.2.1.4.

Agglomeration chemistries
Cross-linking chemistries are well known in bioconjugation of proteins

and other molecules [21]. These techniques have been utilized to couple particles
together. In earlier studies carbodiimide, NHS ester, and imidoester linkers have
been used for agglomerating both polymer particles and liposomes [38].
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In this work the following imidoester and NHS linker chemistries have
been investigated for cross-linking liposomes:
a)

DTBP

(dimethyl

3,3’-dithiobispropionimidate•2HCl)

is

a

homobifunctional imidoester that reacts with primary amines to form stable
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Figure 8. Reaction scheme for DTBP agglomeration [21] followed by cleavage with DTT.
covalent bonds. In mildly alkaline pH’s (7-10), DTBP reacts with aminecontaining molecules forming charged amidine bonds. The disulfide bond on the
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linked conjugate can be cleaved with a strong thiol like DTT (Dithiothreitol) at 37
0C.

The reaction scheme for DTBP is illustrated in figure 8.
b)

DTSSP

(Dithiobis[succinimidylpropionate])

is

a

water-soluble,

homobifunctional N-hydroxysuccinimide (NHS) ester. This cross-linker is active
towards the primary amines resulting in a covalent amide bond and the release
of N-hydroxysuccinimide. The reaction scheme is illustrated below in figure 9.
This is also a thiol cleavable linker well known to be cleavable by DTT.
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Figure 9. Agglomeration scheme for DTSSP agglomeration [21].
It was found that this linker is also cleavable by a mild thiol like cysteine,

26

as witnessed by the size reduction of agglomerates made with DTSSP on
incubation with cysteine.

2.2.2.

Triggered release of drug
With the goal of ‘in vivo’ post-inhalation modulation of drug release rate,

a DTB-urethane conjugate cleavable by an ‘in vivo’ acceptable compound such as
cysteine [27] was developed in our lab. In vitro results showing release and size
reduction was demonstrated [8]. However, with the finding that DTSSP, a
commercially available cross-linker, is cleavable by cysteine, and also the limited
success with the synthesis of a clean DTB-urethane conjugate in considerable
quantities for the studies to be undertaken, the triggered release studies in
animals were done based solely on the DTSSP linkage with no DTB coupled to
the PEG-lipid.

2.2.2.1.

Using cysteine as a trigger
In order for cysteine to act effectively as a cleaving agent to the AVT

particle, the required concentration of cysteine in the lung surfactant should be
below 300 mM representing a total amount of about 1 gram. L-cysteine and its
derivative N-acetyl-L-cysteine (NAC) are available as commercial dietary
supplements from numerous manufacturers. Cysteine is an amino acid which is
commonly found in food and synthesized by the body. NAC helps break down
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mucus (for that reason, inhaled NAC is used in hospitals to treat bronchitis),
increase levels of the antioxidant glutathione, and detoxify harmful substances in
the body. Mucomyst® brand of acetyl-cysteine (Bristol Laboratories), a mucolytic
agent for inhalation, requires a maintenance dose of 6 grams for an adult with a
body weight of 80 kg. Hence, the needed dose of cysteine as a cleaving agent is
not considered forbidden for ‘in vivo’ use at this preliminary stage of this work.

Chapter 3
Methods and Experimental Procedures
3.1.

Analytical Methods
The methods and techniques that were used in the study for

characterizing the particles and assaying the drug are discussed briefly here.

3.1.1.

Dynamic Light Scattering
The parent liposomes that were fabricated and used in the study were in

the submicron range. For measuring such small particles, Dynamic Light
Scattering (DLS) is a very popular and useful technique [39]. Light incident on
particles in solution is scattered in all directions. The light scattered by different
particles is of different phase. The DLS technique is dependent on the molecular
diffusion rate, and monitors the time-dependence of intensity of light scattered
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from the particles. The rate at which the intensity fluctuates about its average
value is dependent on the rate at which the molecules move in solution. The
timescale on which the intensity domain fluctuation takes place is approximately
equal to the time required by two molecules to diffuse far enough relative to each
other such that the phase difference between the two, changes from zero to π
radians. The intensity domain output is transformed into a time domain output
by autocorrelation. The measured autocorrelation function G(τ) is given as
G(τ) = A[1 + B | g(τ) |2]

…

(3.1)

where,
A → baseline value,
B → machine constant,
g(τ) → normalized first-order autocorrelation function.
For a monodisperse system of particles g(τ) becomes a simple exponential
decay, and equation (3.1) is transformed to:

G(τ) = A[1 + B exp(-2Dq2τ)]

…

where,
D → coefficient of diffusion,
q → scattering vector [q = (4π/λ)sin(θ/2)],
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(3.2)

λ→ wavelength of laser in air,
θ → angle of scatter,
τ → time.
For a Newtonian fluid and spherical particles, the diffusion coefficients
are related to the hydrodynamic diameter of the particles by the Stokes-Einstein
equation as,
D = kBT/(3πηd)

…

(3.3)

where,
kB → Boltzmann’s constant,
T → absolute temperature in oK,
η → viscosity of the liquid,
d → particle diameter.
The DLS measurements for this study were done on a Brookhaven
Instruments BI-9000AT Digital Autocorrelator, a BI-200SM goniometer and a
Hamamatsu photomultiplier (Brookhaven Instruments Corp., Holtsville, NY,
USA). The light source was a 532 nm, Ti-sapphire, frequency doubled laser. For
the DLS measurement, the liposomal suspensions were appropriately diluted in
the buffer used to prepare the liposomes.
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3.1.2.

Fraunhofer Diffraction Pattern Analysis
Fraunhofer diffraction is widely used for characterizing particles in the 1-

Figure 10. Fraunhofer Diffraction Pattern Analysis system [41].
200 µm size range [40, 41]. The sample is normally a liquid or gas suspension of
particles whose size distribution is to be determined. Laser energy from the
source is scattered by the particles, resulting in a characteristic energy
distribution at small angles of deviation from the forward beam. A portion of this
scattered pattern is focused onto a detector by a lens of known focal length. A
schematic of a typical Fraunhofer diffraction experiment is shown in figure 10.
The detector response is averaged over a period of time and recorded. The size
distributions are determined by numerically inverting the recorded pattern. For a
monodisperse system of spherical particles in the sample which are larger than
the wavelength of the light used, the diffraction pattern would be described by
the characteristic Airy diffraction equation:
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. . . (3.4)

I(θ) is the scattered intensity at any angle θ, λ the wavelength of the
incident light, D the diameter of the particles in the sample, and n(D) the particle
size (number) distribution.
This pattern is then refracted by a transform lens (of finite aperture) onto a
detector of finite diameter. Neglecting the aberrations due to finite aperture, the
transformed pattern can be obtained by the following transformation:

r = fθ

. . . (3.5)

Where, f is the focal length of the lens and r is the radial position of the
pattern.
The light energy within any detector ring on the focal plane bounded by
radii s1, s2 due to a particle of radius r is given by:
L s1,s2 = E{Jo2(krs1/f) + J12(krs1/f) – Jo2(krs2/f) – J12(krs2/f)}

. . . (3.6)

where,
f → focal length,
E → energy falling on the particle that is proportional to the cross
sectional area of the particle,
Jo, J1 → Bessel functions of the zeroth and first order respectively and first
kind.
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For a collection of particles of different sizes, the total energy is a sum over
all the sizes and is given as:
M

Ls1,s2 = C

∑

Ni {(Jo2 + J12)s1 – (Jo2 + J12)s2}

. . . (3.7)

i

where,
C → proportionality constant,
Ni → number of particles of a particular size.
The detector response (normally a voltage or a current, depending on the
energizing and analysis circuitry), which is proportional to the incident energy is
then given by;
Vs1,s2 = C’ .Ls1,s2

. . . (3.8)

The size distribution can then be calculated from the detector response by
using several methods. The two most popular methods used are the modeldependent and the model-independent methods. The model dependent method
assumes a model such as the Log-Normal or Rosin-Rammler for the size
distribution. The utility of the model-dependent inversion technique is limited to
unimodal distributions. The model-independent technique tackles the more
general multimodal distributions which makes no such assumptions. However,
the number of available detector channels also limits the number of size classes
which can be included in the model-independent analyses. This is normally 32
classes.
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The Fraunhofer Diffraction Pattern Analysis method works very well for
unimodal systems. For sharp-peaked multimodal systems, there is a strong
tendency to skew the distribution towards the mode that contributes the
strongest peak in the diffraction pattern. In the presence of small particles (<1
μm, just below the lower limit of the FDPA system), the modes of multimodal
distributions can be assigned incorrect mass fractions.
It should be noted that the Fraunhofer theory is based on the ideal case of
hypothetical particles. In reality, particles could be non-spherical, and possess
refractive indices that are close to that of the medium. If the particles were
multimodal with a mode larger than the upper limit on size, the measurement
would be inaccurate.
A Malvern Mastersizer (Malvern Instruments Inc., Southborough, MA,
USA) with a 100 mm lens was used to do the FDPA on the agglomerated
liposomes.

3.1.3.

Cascade impaction for aerodynamic characterization of aerosols
Aerosol particles can be spherical or highly irregular in shape. Due to a

variety of shapes, it is difficult to describe an aerosol particle by a single number
like diameter. One way of describing the size of a particle is by the description of
equivalent aerodynamic diameter. The aerodynamic diameter of a sphere can be
equated to its geometric diameter by deriving from Stokes Law as,
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Daer = Dgeo ⋅ ρ

. . . (3.9)

where, Daer is the aerodynamic diameter, Dgeo is the geometric diameter, and ρ is
the specific gravity of the particle with respect to water.
Cascade impactors have been widely used to characterize the
aerodynamic size distribution of aerosol particles. The working principle
involves the drawing of ambient air through the inlet port into a series of stages
connected by successive smaller orifices. The number of stages is typically 6 to 7.
As the aerosol particles flow through the stages of the device, they are propelled
toward the collection plates on each stage with increasingly higher inertia. If the
particle has sufficient inertia, it will impact the plate; else it will be carried by the
air flow into the successive stage. Submicron particles that are not collected on
the last collection plate are caught up in the backup filter, immediately
downstream from the last stage. Once the sampling is complete, the amount
deposited on each stage is determined. The measurement results in a size
distribution of the aerosol particles.
An Andersen Cascade Impactor, series 20-800, 1 ACFM non-viable
sampler (Thermo Electron Corp., Waltham, MA, USA) was used to determine the
aerodynamic diameters of the agglomerates.
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3.1.4.

Microscopy
Microscopy is a widely used technique that produces visible images of

structures or details that are too small to be seen by the eye, by using either a
microscope or a magnification tool.
In conventional microscopy, the resolution of the image depends on the
wavelength of the incident radiation, which could be light, electron beam, or an
X-ray. The lower wavelength of electron beam results in an image with higher
resolution.
The techniques discussed below were used to evaluate the morphology
and size of the agglomerates:

3.1.4.1.

Confocal Laser Scanning Microscopy
Confocal laser scanning microscopy (CLSM) is a valuable tool for

obtaining high resolution images and 3-D reconstructions. The key feature of
confocal microscopy is its ability to produce blur-free images of thick specimens
at various depths. Images are taken point-by-point and reconstructed with a
computer, rather than projected through an eyepiece.
In a laser scanning confocal microscope, a laser beam passes a light source
aperture and is then focused by an objective lens into a small (ideally diffractionlimited) focal volume within a fluorescent specimen. A mixture of emitted
fluorescent light as well as reflected laser light from the illuminated spot is then
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recollected by the objective lens. A beam splitter separates the light mixture by
allowing only the laser light to pass through and reflecting the fluorescent light
into the detection apparatus. After passing a pinhole, the fluorescent light is
detected by a photo-detection device [photomultiplier tube (PMT)] transforming
the light signal into an electrical one which is recorded by a computer

Beam
Splitter

Focal plane

Light
source
Aperture

Reflector

Objective
lens

Aperture
Detector

Figure 11. Working principle of confocal microscopy.

The agglomerates (encapsulating carboxyfluorescein dye) in this study
were imaged with a Zeiss LSM 510 META confocal microscope using a ×63
immersion oil objective (Carl Zeiss, Germany).
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3.1.4.2.

Negative Staining Electron Microscopy
Electron microscopes were developed to overcome the limitations of light

microscopes, which are limited by the physics of light to 1000X magnification
and a resolution of 0.2 µm. They are able to achieve 10,000X plus magnifications
that are just not possible using light microscopes. By achieving these
magnifications, finer details of a specimen can be observed with a resolution in
the nanoscale length limits.
An electron microscope uses a highly energetic beam of electrons that is
focused on a specimen to examine objects on a very fine scale. The examination
can yield information on; (1) the surface features of the object (topography), (2)
shape and size of the particles that make up the object (morphology), (3) the
elements and compounds that make up the object (composition), and (4) the
crystallographic information of the specimen.
Most biological materials show little contrast with their surroundings
unless they are stained. In the case of light microscopy, contrast can be enhanced
by using colored stains which selectively absorb certain wavelengths. The
electrons in the electron microscope are absorbed very little by biological
material and contrast is obtained mainly by electron scattering.
To heighten the contrast between the specimen and the background,
electron-dense "stains" are used. These are usually compounds of heavy metals
of high atomic number (for e.g. uranium salts), that serve to scatter the electrons
from regions covered with the stain. If particles are coated with stain (positive
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staining), fine details may be obscured. Negative staining overcomes this
problem by staining the background and leaving the particle relatively
untouched. The negative stain is molded round the particle, outlining its
structure, and is also able to penetrate between small surface projections and to
delineate them.
In this study, negative stained electron micrographs of agglomerates and
liposomes were taken with a JEOL JEM1230 electron microscope operating at 80
kV and 56 µA beam current.

3.1.5.

HPLC assay
Chromatography is a general technique that separates a mixture into its

individual components in order to evaluate each component, free from
interference, from the other components. Chromatography can be coupled with a
detection system that would enable a characterization of each component. High
performance liquid chromatography (HPLC) is one such method. It is used to
analyze liquid samples or the liquid extract of a sample.
The fundamental basis for HPLC consists of passing a sample (chemical
mixture) in a high pressure solvent (the mobile phase) through a packed bed of
adsorbents (the stationary phase). As the chemical entities pass through the
column they interact between the two phases; mobile and stationary, at different
rates. The difference in rates is primarily due to different polarities of the
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components. The components that have the least amount of interaction with the
stationary phase or the most amount of interaction with the mobile phase will
exit the column faster. Repeated interactions along the length of the column
result in a separation of the entities. Various mixtures of the chemicals can be
analyzed by changing the polarities of the stationary phase and the mobile
phase.
The stationary phase is typically bonded to a support phase, usually
consisting of porous beads. The pore sizes can be varied to control the elution
rate of different species. Furthermore, the dimensions of the column can also be
varied to enable further control over the separation.
A change in the polarity of the mobile phase can significantly affect the
efficiency of any HPLC separation. The mobile phase polarity is generally the
opposite of the stationary phase. The rate at which the polarity is changed
defines the "gradient." This gradient technique helps to further separate mixtures
of variously polar components.
As the components exit the column, they can be detected by various
means. Refractive index, electrochemical, or ultraviolet-absorbance changes in
the mobile phase can indicate the presence of a component. The amount of the
particular component leaving the column will determine the intensity of the
signal produced in the detector. The detector measures a signal peak as each
component leaves the column. By comparing the time it takes for the peak to
show up (the retention time) with the retention times for a mixture of known
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compounds, the components of unknown sample mixtures can be identified. By
measuring the signal intensity (response) and comparing it to the response of a
known amount of that particular component, the amount of the component in
the mixture can be determined.
The HPLC system used in the studies for assaying Ciprofloxacin consisted
of a Shimadzu SCL-10Avp liquid chromatograph, SPD-10Avp UV-Vis detector
(278 nm) and SIL-10Advp auto-injector (Shimadzu Scientific Instruments,
Columbia, MD, USA). The chromatographic conditions were as follows:
Chromatography was carried out with a Waters Symmetry 5µ C18 column, 150 x
4.6 mm (Waters Corp, Milford, MA, USA); The column temperature was
maintained at 28°C and the flow rate was 1.0 mL per minute; The mobile phase
was a mixture of 15% (v/v) acetonitrile and 85% (v/v) 25 mM sodium phosphate
buffer at pH ~ 2.3. The sample injection volume was 20 µL. Ciprofloxacin eluted
within 10 minutes, under these assay conditions.

3.2.

Experimental procedures of the 1st generation of AVT (in vivo
non-cleavable)
In this section preliminary experiments that were undertaken are

described. The early studies were done with blank liposomes (no drug
encapsulated). The focus of these studies was to see how different reaction
conditions, such as the amount of reacting groups, and pH of the reaction,
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affected the agglomeration of liposomes. Ciprofloxacin was used as a model
drug to investigate in vitro release characteristics of the agglomerates in addition
to the aerodynamic properties of the agglomerated vesicles. Finally the
agglomerates of DTBP (in vivo non-cleavable) encapsulating Ciprofloxacin were
evaluated for drug release properties in vivo, by instilling formulations in the
lungs of normal rabbits.

3.2.1.

In vitro experiments with blank liposomes

3.2.1.1.

Materials
1,2-Dipalmitoyl-sn-Glycero-3-Phosphatidylcholine (DPPC) was purchased

from Genzyme Pharmaceuticals (Cambridge, MA, USA). Cholesterol was
purchased

from

Sigma-Aldrich

(St.

Louis,

MO,

USA).

Distearoyl

phosphoethanolamine [Amino (polyethylene glycol)] (DSPE-PEG-NH2) conjugate
was purchased from Avanti Polar Lipids Inc (Alabaster, AL, USA). The crosslinker DTBP was purchased from Pierce (Rockford, IL, USA). All the rest of the
reagents were purchased from Fisher Scientific.

3.2.1.2.

Fabrication and characterization of liposomes
The liposomes were made by extruding a suspension of dissolved

hydrated lipids through a single 400 nm Whatman Nuclepore polycarbonate
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trach-etch membrane in a Lipex Biomembranes extruder (Vancouver, British
Columbia, Canada). A lipid composition of 57-58% DPPC, 40% Cholesterol, and
2-3% DSPE-PEG-NH2 conjugate was used. The lipids were dissolved in ethanol
at 50-600 C and then hydrated with sodium citrate buffer (ethanol volume not
exceeding more than 10% of the final volume), the lipid concentration in the final
mixture being 50-100 mM. The suspension was then passed 7-10 times through
the extruder at 50-540C and a pressure of approximately 100 psi.
Assuming 51% of the DSPE-PEG-NH2 to be on the outer leaflet of the
bilayer, the number of amine groups available for coupling with the cross-linker
were estimated to be 0.26 x 10-6 moles/ml (10 mM lipid), 0.51 x 10-6 moles/ml (20
mM lipid), and 1.28 x 10-6 moles/ml (50 mM lipid). The liposomes were
characterized by Dynamic Light Scattering (DLS).
3.2.1.3.

Fabrication and characterization of agglomerates
Liposomes were agglomerated using DTBP. Liposomes at a lipid molarity

of 10, 20, and 50 mM were used for the agglomeration. The amount of DTBP
used in the reactions were 25, 50, and 100 fold molar excess over the number of
PEG-NH2 groups on the outer leaflet of the liposomes. The pH of the liposomes
was monitored and maintained at ~8.15 (the optimal pH for DTBP activity is in
the 8-9 range) with NaOH solution, and the linker was added to the liposomes
with constant stirring for over 3 hours. The reaction was carried at room
temperature.
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To investigate the extent of the agglomeration process at various time
points, aliquots of the reaction mixtures were taken and added to a buffered
solution of 300 mM Tris. Tris is used as a quencher to arrest the reaction of the
imidoester - DTBP, by providing free primary amines to the cross-linker.
The sizes of the agglomerates were determined by the Fraunhofer
diffraction technique.

3.2.2.

In vitro studies with Ciprofloxacin loaded liposomes

3.2.2.1.

Materials
DPPC was purchased from Genzyme Pharmaceuticals (Cambridge, MA,

USA). Cholesterol was purchased from Sigma-Aldrich (St. Louis, MO, USA).
DSPE-PEG-NH2 conjugate was purchased from Avanti Polar Lipids Inc
(Alabaster, AL, USA). The cross-linker DTBP was purchased from Pierce
(Rockford, IL, USA). Ciprofloxacin (Bayer Pharmaceutical Corp, West Haven,
CT, USA) was purchased from a local pharmacy as Cipro-I.V. solution and
purified as follows: The pH of Cipro-I.V. solution was raised from 2.1 to 7 with
sodium hydroxide to precipitate the Ciprofloxacin. The suspension was then
centrifuged at 1500 x g (4000 rpm) for 10 minutes, and the supernatant discarded.
The powder was then washed with DI water and centrifuged 4 times to remove
lactic acid (an inert excipient in the i.v. solution). A final wash and centrifugation
with ethanol yielded a wet powder which was collected and dried in a vacuum
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desiccator. Ciprofloxacin yield was 90%. Survanta® was purchased from Abbot
Laboratories (Abbott Park, Illinois, USA). All the rest of the reagents were
purchased from Fisher Scientific (Hampton, NH, USA).
3.2.2.2.

Fabrication and characterization of liposomes
The liposomes were made by extruding a suspension of dissolved

hydrated lipids through a single 400 nm Whatman Nuclepore polycarbonate
trach-etch membrane in a Lipex Biomembranes Extruder. A lipid composition of
55% DPPC, 40% Cholesterol, and 5% DSPE-PEG-NH2 conjugate was used. The
lipids were dissolved in ethanol at 50-600 C and then hydrated with 300 mM
ammonium sulfate solution (ethanol volume not exceeding more than 10% of the
final volume), the lipid concentration in the final mixture being 75 mM. The
suspension was then extruded 7 times at 50-600C and a pressure of
approximately 100 psi.
Assuming 51% of the DSPE-PEG-NH2 to be on the outer leaflet of the
bilayer, the number of amine groups available for coupling was estimated to be
1.92 x 10-6 moles/ml (75 mM lipid). The liposomes were characterized by DLS.

3.2.2.3.

Loading of liposomes with ciprofloxacin
Ciprofloxacin was loaded into liposomes of 75 mM lipid content by the

ammonium sulfate gradient method [36]. Blank liposomes were prepared in a
300 mM ammonium sulfate solution. 10 mL of the liposomes were dialyzed
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(using 100,000 MWCO dialysis tubing) for 4 hours against 300 mL of saline at pH
of 5.2 (adjusted by HCl) in order to remove ethanol and ammonium sulfate from
the external phase of the liposomes and to establish the proton/sulfate gradient.
Ciprofloxacin was dissolved in saline at pH 4.2 and 52ºC. The solution of
Ciprofloxacin (15 mL) was added gradually to the liposomal suspension (15 mL)
and the temperature was maintained at 52ºC. The remote loading procedure was
terminated after 1 hour by rapidly dropping the temperature using an ice bath.
The drop in temperature reduces the permeability of the liposome bilayer thus
preventing the transfer of species across the bilayer and entrapping the loaded
drug. Finally, the liposomal suspension was dialyzed for 4 hours against 300 mL
of saline at pH 5.2 to remove unencapsulated Ciprofloxacin. The final lipid
content of the Ciprofloxacin-loaded liposomes was 37.5 mM.
Dialysis (using 100,000 Dalton MWCO tubing) was used to evaluate the
encapsulated fraction of drug. The Ciprofloxacin-loaded formulations were
dialyzed against saline at pH 5.2. The volume of the external buffer was 100
times the volume of the liposomal formulation. Samples were taken from the
external phase and were assayed. Complete removal of the unencapsulated drug
was considered to be achieved, when the external phase concentration remained
unchanged for 6 hours. Then, the formulation was removed from the dialysis
tubing, lysed with methanol (30% of total volume), and assayed by HPLC to
measure the encapsulated amount of drug.
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3.2.2.4.

Agglomeration

and

characterization

of

Ciprofloxacin-loaded

liposomes
Liposomes were agglomerated using DTBP. The coupling reaction of the
PEG-amines with DTBP was carried out in pH of 5.2 (same pH as for
Ciprofloxacin loading) or 8.5 (optimal pH for linker activity) in saline. This was
done to determine the pH that would be best suited for the agglomeration and at
the same time would not result in drug leakage. The amount of DTBP used was
100-fold molar excess of the NH2 groups on the PEG.
The cleavage of the DTBP agglomerates was accomplished with
dithiothreitol (DTT) at 37 0C. The sizes of the agglomerates were determined by
the Fraunhofer diffraction technique.

3.2.2.5.

Aerodynamic properties of agglomerates
The aerodynamic properties of the agglomerated liposomes containing

Ciprofloxacin were evaluated by nebulizing 2 ml of the formulation into an
Andersen Cascade Impactor (Series 20-800, 1 ACFM non-viable sampler). A
Parijet LC nebulizer was used for the cascade impactor study. The impactor was
operated under ambient conditions (24 ± 1 0C and ~ 55% relative humidity) at
constant flow rate of 28.3 L/min (calibrated by the supplier). The vacuum pump
connected to the impactor was started and the sample was nebulized into the
cascade impactor for 15 minutes, sufficient to nebulize the entire contents. Finlay
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et al. have emphasized the problems of droplet undersizing [42, 43] in a cascade
impactor run at ambient conditions, due to heating of the nebulized air. They
demonstrate mass mean aerodynamic diameters (MMADs) under ambient
conditions to be 1 µm lower than under saturated air conditions. However, it is
also known that that this shrinkage will be less in a larger droplet due to the
lower surface area/unit volume. We have therefore operated the nebulizer and
cascade impactor at ambient conditions, which is consistent with the USP
method (USP 23, NF 18, <610>, 1995).
At the end of the nebulization run, each plate of the impactor, the elbow
piece, and the filter paper at the end of the last stage were washed several times
with 10 ml of saline at pH ~ 5.2. Methanol (30% of total wash buffer by volume)
was used to lyse the liposomes collected on each stage. These washes were then
analyzed by HPLC to determine the amount of Ciprofloxacin collected on each
stage. The amount of Ciprofloxacin on each stage was then assigned to the
corresponding aerodynamic diameter of each stage to determine the
aerodynamic size distribution.
The weight of the nebulizer containing the formulation was recorded
prior to and at the end of the nebulization in order to estimate the amount of
formulation nebulized into the cascade impactor. It was estimated that more than
95% of the initial charge was nebulized.
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3.2.2.6.

Stability upon nebulization
The effects of nebulization on the size and encapsulation of Ciprofloxacin

were investigated. For this, the core liposomes and agglomerated formulations
were nebulized, using a Parijet LC nebulizer, for a specific time into a conical
flask, (figure 12) which contained 30 mL of saline. The secondary aim of this
experiment was also to determine if the nebulizer was able to deliver the
agglomerates.
The nebulizer loaded with the formulation was weighed before and after
every nebulization. After every nebulization, the device was weighed and a
sample was taken for HPLC analysis of Ciprofloxacin content. This was used to
determine the total amount of formulation nebulized into the flask. At the end of
the experiment, the amount of Ciprofloxacin in the collected nebulisate was
analyzed by HPLC. This was done to estimate the fraction of nebulized material
collected in saline.

Nebulisate

Nebulizer

Collecting buffer
Formulation

Figure 12. Schematic for collecting nebulized formulations of liposomes and
agglomerates for evaluating effects upon nebulization.
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The size of liposomes in the collected nebulisate was determined by DLS,
and the size of the agglomerates in the collected nebulisate was analyzed by
Fraunhofer diffraction. The loss of encapsulated Ciprofloxacin from the
liposomes and agglomerates was evaluated by dialysis (as described previously)
of the collected nebulisate.

3.2.2.7.

In vitro release studies
The release of Ciprofloxacin from agglomerates and liposomes was

evaluated in-vitro. The commercial pulmonary surfactant replacement Survanta®
was

used

to

simulate

the

lung

environment.

Ciprofloxacin-loaded

liposomes/agglomerates and Survanta® (3:1 volumetric ratio respectively) were
incubated at 37 °C in a dialysis bag (100,000 MWCO) immersed in PBS at a pH of
7.4. The volume of the external phase was 25 times that of the internal phase.
Samples from the external phase were taken and were assayed for Ciprofloxacin
in the HPLC. At the end of the experiment the contents of the dialysis bag were
also assayed for Ciprofloxacin content.

3.2.3.

In vivo studies of Ciprofloxacin loaded liposomes
To evaluate the drug release properties of the agglomerates made with

DTBP (in vivo non-cleavable) in vivo, formulations of liposomes and
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agglomerates were instilled in the lungs of rabbits. The experimental procedures
are noted below.

3.2.3.1.

Materials
DPPC

and

methoxypoly

(ethylene

glycol)

distearoylphosphatidyl

ethanolamine (MPEG-DSPE) were purchased from Genzyme Pharmaceuticals
(Cambridge, MA, USA). Cholesterol (CHOL) was purchased from Sigma-Aldrich
(St. Louis, MO, USA). DSPE-PEG-NH2 conjugate was purchased from Avanti
Polar Lipids (Alabaster, AL, USA). DTBP was purchased from Pierce (Rockford,
IL, USA). Ciprofloxacin (Bayer Pharmaceutical Corp., West Haven, CT, USA)
was purchased from a local pharmacy as Cipro-I.V. solution and was purified as
described in section 3.2.2.1. All other reagents were purchased from Fisher
Scientific (Hampton, NH, USA).

3.2.3.2.

Animals
New Zealand White male rabbits (2.9 ± 0.5 kg) were purchased from

Myrtle Rabbitry (Thompson Station, TN, USA). The use of animals for this study
was approved by the Center for Laboratory Animal Medicine and Care
(CLAMC) of UTHSC-Houston. Care and handling of the animals was in
accordance with all policies of the United States Department of Agriculture
(USDA) and U.S. Public Health Service (PHS).
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3.2.3.3.

Fabrication and characterization of liposomes
Two separate batches of liposomes (~120 mM lipid content) were

prepared. A lipid composition of DPPC:CHOL:DSPE-MPEG (57:40:3, mol%)
(MPEG terminated, for studies with liposomes), and DPPC:CHOL:DSPE-PEGNH2 (57:40:3, mol%) (amino terminated, for making AVT) was used. The lipids
were dissolved in ethanol at 550 C and then hydrated with a 400 mM ammonium
sulfate solution (ethanol volume not exceeding more than 10% of the final
volume). The liposomes were made by extruding the suspension of the hydrated
dissolved lipids through a single 400 nm Whatman Nuclepore polycarbonate
trach-etch membrane in a Lipex Biomembranes extruder (Vancouver, British
Columbia, Canada). The suspension was then passed 7-10 times through the
extruder at 50-54 0C and a pressure of approximately 100 psi. The liposomes
were characterized by DLS.

3.2.3.4.

Loading of liposomes with Ciprofloxacin

Ciprofloxacin was loaded into liposomes by the ammonium sulfate
gradient method [36]. Liposomes were diafiltered for 1-2 hours using 50 nm
cutoff tubings with the external phase of the liposomes being replaced with
saline (150 mM) at pH of ~5.3 in order to remove ethanol and non-encapsulated
ammonium sulfate. For the remote loading procedure, Ciprofloxacin was
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dissolved in saline (60 mg/ml) at pH 4.2 and 60ºC, and was gradually added (0.5
ml added every 3-5 minutes) to the liposomal suspension with the temperature
maintained at 60ºC. The loading was terminated after 1 hour by rapidly
dropping the temperature using an ice bath. The drop in temperature reduces the
permeability of the liposome bilayer thus preventing the transfer of species
across the bilayer and entrapping the loaded drug. Finally, the suspension was
separated from unencapsulated Ciprofloxacin by overnight dialysis against
saline solution (100 times volume of liposomes) at pH 5.3.
3.2.3.5.

Agglomeration

and

characterization

of

Ciprofloxacin-loaded

liposomes
Liposomes containing 3% PEG-NH2 conjugate in the lipid bilayer were
agglomerated using DTBP as the linker. The amount of DTBP used was a 50 fold
molar excess over the number of PEG-NH2 groups on the outer leaflet of the
liposomes. The pH of the liposomes was raised from 5.3 to 8.5 (the optimal pH
for DTBP activity is in the 8-9 range) with NaOH solution, and the linker was
added to the liposomes with constant stirring for 1.5 hours after which the pH
was dropped to 5.3 to arrest the cross-linking reaction.
The sizes of the agglomerates were determined by the Fraunhofer
diffraction technique.
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3.2.3.6.

Pharmacokinetic study in rabbits
Rabbits

were

anesthetized

by

a

subcutaneous

injection

of

ketamine/xylazine (40-50/5-10 mg/kg). The rabbits were maintained on 2%
isoflurane and O2 (1 lit/minute). The heart rate, temperature and O2 were
monitored periodically, and remained stable throughout the course of the
experiment.
The marginal ear vein was accessed via an i.v. catheter (24 G). The catheter
was taped to the ear. Using a laryngoscope, an endotracheal tube (size 3) was
inserted into the trachea, with a urinary catheter acting as a guide. Insertion into
trachea was confirmed with a stethoscope, by pumping air into the lungs. The
cuff of the endotracheal tube was filled with air to maintain the tube in the
trachea. Additionally, the tube was tied to the mouth to retain it in place.
The rabbit’s head was maintained in an upright position and drug
formulation was instilled into the lungs with a syringe. The formulation was
pushed down by forcing air into the lungs with the syringe several times. 2.2 to
2.8 ml of formulation (corresponding to Ciprofloxacin doses of 17 ± 1.6 mg/kg)
was instilled.
Blood was drawn from the ear vein before (time 0) and after instillation of
drug formulation. Blood samples were centrifuged at 13,400 rpm for 15 minutes
to separate the plasma from cell components. The plasma was then diluted 1:4
times with methanol: phosphate buffer (9:1 v/v) to precipitate the proteins
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present in the sample. The resulting suspension was then centrifuged at 13,400
rpm in a microcentrifuge for 15 minutes and the supernatant was assayed for
Ciprofloxacin content by HPLC. Standard curve for Ciprofloxacin was
determined by spiking known amounts of Ciprofloxacin in rabbit plasma. The
lowest detection limit by HPLC was 0.05 µg/ml.
The following formulations were instilled into the lungs:
a)

Free Ciprofloxacin solution.
Ciprofloxacin was dissolved in normal saline at a concentration of 21.9

mg/ml. The pH of the solution was adjusted to approximately 3.1 to maintain
Ciprofloxacin in solution. This solution was then instilled into the lungs of the
rabbits as described above.
b)

Liposome-encapsulated Ciprofloxacin
The instillation of the Stealth® liposomes was as described by the

procedure above. The final lipid content of the liposomes that were instilled was
~110 mM.
c)

AVT1
AVT particles made with the cross-linker DTBP that were used for the

pharmacokinetic studies in rabbits are referred to as AVT1. These agglomerates
are not susceptible to cysteine cleavage. They were instilled according to the
procedure described above. The final lipid content of the AVT1 that was instilled
was ~50 mM.
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3.2.4.

In silico study of Ciprofloxacin pharmacokinetics of the 1st
generation AVT
A deterministic compartmental model was employed to analyze the

Ciprofloxacin profiles obtained from the pharmacokinetic studies. The model
shown in Figure 13 consisted of 4 compartments with most of pharmacokinetics
being assumed first order. In order to understand the pharmacological
phenomena and the related physiological meaning, possible release mechanisms
of Ciprofloxacin from the AVT particle were proposed by introducing the
“particle” compartment.

Bolus β
Particle
VAVT CAVT

Bolus α
kAVT

kL

Lungs
VL CL
kL0

Blood
CB VB

k12
k21

Periphery
CP

k10

Figure 13. Sketch of the compartmental model.

It was hypothesized that 2 mechanisms are important to describe the
release from the liposomes and AVT particles:

56

1.

Once the liposomes and agglomerate microparticles were instilled into the
lungs of the rabbit, forces due to motion of the lungs caused a degree of
fragmentation resulting in immediate release of a portion of the
encapsulated drug. Therefore, the input amount into the “particle”
compartment was the total load of Ciprofloxacin into the particle
subtracted by “α” which is used to represent the amount leaked from the
AVT particle due to fragmentation (equation 1). It is assumed that shear
forces are experienced by the particle until the particle comfortably
reorients itself. The reorientation was assumed to occur instantaneously
upon deposition in the lungs.

2.

The second mechanism of release was attributed to a diffusion process
represented with the first order rate constant kAVT in equation 2. The drug
molecule is assumed to diffuse initially through the liposomal wall and
then through the matrix of the agglomerate.
Input Bolus= β =

D- α
VAVT

D
initial dose of Ciprofloxacin (µg)
amount of Ciprofloxacin leaked from particles due to disruption (µg)
α
VAVT internal volume of the liposomes (ml)
dC AVT
= − k AVT ⋅ C AVT
dt
CAVT Ciprofloxacin concentration in the “particle” compartment (µg/ml)
kAVT first order constant to the “lung” compartment (hr-1)
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(1)

(2)

In the case of the liposomes, the subscripts with “AVT” are replaced with
“Lips”.
In the case of the “lung” compartment, the elimination rate could be
attributed to (a) transport of the Ciprofloxacin molecule to the lymphatic
circulation, and (b) macrophage uptake of liposomes, and agglomerates when
their fragments fall into geometrical sizes (due to size decrease induced by
rupture due to the motion of the lungs) within the macrophage uptake range.
The total clearance is described via the first order elimination process (kL0).
Besides the elimination rate and the flux towards the “blood” compartment (both
first order), a bolus input (α) was introduced which represents the amount of
drug

that

leaked

from

the

AVT

particles

(or

liposomes)

during

reorientation/fragmentation.

Input Bolus=

VL
CL
kL0
kL

α
VL

dC L
= k AVT ⋅ C AVT − (k L + k L0 ) ⋅ C L
dt
volume of the pulmonary surfactant (mL)
Ciprofloxacin concentration in the “lung” compartment (µg/ml)
first order elimination constant (hr-1)
first order constant towards the “blood” compartment (hr-1)

(4)

(5)

The “blood” compartment was assumed to communicate with the lung
compartment and a “periphery” compartment with elimination of the drug due
to hepatic and renal clearance mechanisms.
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CB
VB
Cp
k12, k21
k10

dC B
= k L ⋅ C L − (k10 + k12 ) ⋅ C B + k 21 ⋅ C P
dt

(6)

dCP
= k12 ⋅ CB − k21 ⋅ CP
dt

(7)

Ciprofloxacin concentration in the “blood” compartment (µg/ml)
blood volume (mL)
Ciprofloxacin concentration in the “periphery” compartment (µg/ml)
first order constant towards and from the “periphery” compartment (hr-1)
first order constant for elimination of drug from blood compartment (hr-1)

Colino et al. investigated the response of i.v. injection of Ciprofloxacin in
rabbits [44]. The parameters that were estimated in the study were fixed in this
work and are tabulated in table 1. The model given by equations (1)-(7) was
fitted to the Ciprofloxacin levels in the blood of animals treated with the
liposomes, and AVT. For the estimation of the PK parameters a non-linear
extended least squares regression analysis, as implemented in the SAAM II
software (University of Washington and SAAM institute, Seattle, WA) was used.

Table 1. Pharmacokinetic parameters fixed from literature
Parameter

Value

k12

3.06 (hr-1)

k21

1.25 (hr-1)

k10

1.7 (hr-1)

The integrator was based on the Rosenbrock method and the optimizer
was a modification of Gauss-Newton method [45-47]. The objective function that
was minimized was the following extended least squares function:
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[

]

2
N
1 J j  yi,j − s(p, t i,j )
OBJ = ∑∑ 
+ logVi,j s(p, t i,j ), yi,j , v i,j
M j=1 i=1  Vi,j s(p, t i,j ), yi,j , v i,j

[

]

[

M

the sum of all data points across all data sets

yi,j ti,j

the i-th data and time point in the j-th data set

p

vector of the estimated parameters

s(p, ti,j)

the model prediction at time i in the j-th data set

Vi,j

the measurement error at time i in the j-th data set

vj

the posteriori variance factor of the j-th data set



]

(8)



In our case the model was used to fit one set of experimental data. Since
the data were expressed as mean value (±standard deviation), the model
accounted for the error of the data.

yobs (t i ) = ycal (t i , p) + ei , i = 1,...,n

yobs

the random vector of measurements

ycalc

known function describing the kinetics

p

the random vector for kinetic model parameters

ej

the measurement error random vector

(9)

The objective function was optimized in order to minimize the difference
between the experimental and the simulated data. Therefore, the objective
function was weighted by the error variance and hence the parameter confidence
limits would be a function of data reliability.
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  y (t ) − y (t )  2

2
calc i
[
(
)
]
OBJ = ∑   obs i
+
ln
S
D
t
i 

SD(t i )
i =1  



n

(10)

Variance = ν = SD2
1
1
Weight = w = =
ν SD2

res (t i ) = y obs (t i ) − y calc (t i )
wres (t i ) = wi [y obs (t i ) − y calc (t i )]

The minimum number of calculation intervals was set at 200 and the
maximum number of fit iterations was set at 50 based on central difference
derivative. The convergence criterion was set to 10-7. Convergence was achieved
when one of the two criterions was satisfied:
1.

The difference between the value of the linear approximation of the
objective function at the current parameter estimate and the minimum
value of the linear approximation was less than ε, where ε equaled 10-7
times the value of the linear approximation at the current parameter
estimate.

2.

The solution to a linear approximation of the objective function was
within δ for each parameter, where the default value of δ equaled 10-7
times the difference between the upper and lower bounds for that
parameter.
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3.3.

Experimental procedures of the 2nd generation of AVT (in
vivo cleavable)
In this section the in vitro and in vivo experiments that were undertaken

to demonstrate modulation of release after cleavage with cysteine are described.
The aliphatic disulfide cross-linker dithiobis[succinimidylpropionate] (DTSSP)
was used in making the agglomerates.

3.3.1.

In vitro studies with blank liposomes

3.3.1.1.

Materials
DPPC was purchased from Genzyme Pharmaceuticals (Cambridge, MA,

USA). Cholesterol was purchased from Sigma-Aldrich (St. Louis, MO, USA).
DSPE-PEG-NH2 conjugate was purchased from Avanti Polar Lipids Inc

(Alabaster, AL, USA). The cross-linker DTSSP was purchased from Pierce
(Rockford, IL, USA). All the rest of the reagents were purchased from Fisher
Scientific.
3.3.1.2.

Fabrication and characterization of liposomes

The liposomes were made by extruding a suspension of dissolved
hydrated lipids through a single 400 nm Whatman Nuclepore polycarbonate
trach-etch membrane in a Lipex Biomembranes extruder (Vancouver, British
Columbia, Canada). A lipid composition of 57% DPPC, 40% Cholesterol, and 3%
DSPE-PEG-NH2 conjugate was used. The lipids were dissolved in ethanol at 50-
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600 C and then hydrated with sodium citrate buffer (ethanol volume not
exceeding more than 10% of the final volume), the lipid concentration in the final
mixture being 100 mM. The suspension was then passed 7-10 times through the
extruder at 50-540C and a pressure of approximately 100 psi. The liposomes were
characterized by DLS.

3.3.1.3.

Agglomeration and characterization of blank agglomerates
Liposomes (~50 mM lipid content) were agglomerated using DTSSP as the

linker. The amount of DTSSP used was a 20 fold molar excess over the number of
PEG-NH2 groups on the outer leaflet of the liposomes. The pH of the reaction
mixture was maintained at ~ 7.4 (the optimal pH for DTSSP activity is in the 7-8.5
range). The linker was added slowly over 10 minutes to the liposomes with
constant stirring, with the agitation maintained for 1.5 hours.
The agglomerates were split into batches and treated with different
amounts of cysteine at 37 0C to induce cleavage of the disulfide linkage in the
cross-linker. The sizes of the agglomerates before and after cleavage were
measured Fraunhofer diffraction.
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3.3.2.

In vitro studies with carboxyfluorescein loaded liposomes

3.3.2.1.

Materials
DPPC was purchased from Genzyme Pharmaceuticals (Cambridge, MA,

USA). Cholesterol and 1,4-diazabicyclo[2.2.2]octane (Dabco) was purchased from

Sigma-Aldrich (St. Louis, MO, USA). DSPE-PEG-NH2 conjugate was purchased
from Avanti Polar Lipids Inc (Alabaster, AL, USA). The cross-linker DTSSP was
purchased from Pierce (Rockford, IL, USA). 5-(and-6)-carboxyfluorescein was
purchased from Invitrogen Corp. (Carlsbad, CA, USA). The other reagents were
purchased from Fisher Scientific.

3.3.2.2.

Fabrication and characterization of liposomes
A lipid composition of 57% DPPC, 40% Cholesterol, and 3% DSPE-PEG-

NH2 conjugate was used. The lipids were dissolved in ethanol at 550 C and then
hydrated with a 5 mM carboxyfluorescein solution made in saline (150 mM
NaCl) (ethanol volume not exceeding more than 10% of the final volume). The
liposomes were made by extruding the suspension of the hydrated dissolved
lipids through a single 400 nm Whatman Nuclepore polycarbonate trach-etch
membrane in a Lipex Biomembranes extruder (Vancouver, British Columbia,
Canada). The lipid concentration in the mixture was 100 mM. The suspension
was then passed 7-10 times through the extruder at 50-54 0C and a pressure of
approximately 100 psi.
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The extruded liposomes were then diafiltered for over 3 hours using 50
nm cutoff tubings with the external phase of the liposomes being replaced with
saline (150 mM) at pH of ~7.2 in order to remove ethanol and unencapsulated
carboxyfluorescein. The diafiltration was stopped when the external phase
collected

during

the

diafiltration

was

colorless.

The

liposomes

were

characterized for size by DLS.

3.3.2.3.

Agglomeration

and

characterization

of

carboxyfluorescein

agglomerates
Liposomes (~50 mM lipid content) were agglomerated using DTSSP as the
linker. The amount of DTSSP used was a 20 fold molar excess over the number of
PEG-NH2 groups on the outer leaflet of the liposomes. The pH of the reaction
mixture was maintained at ~ 7.4 (the optimal pH for DTSSP activity is in the 7 8.5 range). The linker was added slowly over 10 minutes to the liposomes with
constant stirring, with the agitation maintained for 1.5 hours.
The sizes of the agglomerates were characterized by Fraunhofer
diffraction.

3.3.2.4.

Visual analysis of agglomerates by Confocal microscopy
The agglomerates were diluted in saline containing 25 g/L of Dabco to

inhibit the photobleaching of the fluorescent dye. A drop of the diluted
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agglomerates was placed on a glass slide and a cover slip was placed over it. The
agglomerates were observed under a Zeiss LSM 510 META confocal microscope
using a ×63 immersion oil objective (Carl Zeiss, Germany) in the multi-track
scanning mode with excitation wavelengths set at 488 nm (Argon laser); emission
wavelengths were 505 to 530 nm for signal detection. Single optical slices were
set to 0.8 µm and Z-stack slices to 0.5 µm.

3.3.3.

In vitro studies with Ciprofloxacin loaded liposomes

3.3.3.1.

Materials
DPPC was purchased from Genzyme Pharmaceuticals (Cambridge, MA,

USA). Cholesterol was purchased from Sigma-Aldrich (St. Louis, MO, USA).
DSPE-PEG-NH2 conjugate was purchased from Avanti Polar Lipids Inc
(Alabaster, AL, USA). The cross-linker DTSSP was purchased from Pierce
(Rockford, IL, USA). Ciprofloxacin (Bayer Pharmaceutical Corp, West Haven,
CT, USA) was purchased from a local pharmacy as Cipro-I.V. solution and
purified as follows: The pH of Cipro-I.V. solution was raised from 2.1 to 7 with
sodium hydroxide to precipitate the Ciprofloxacin. The suspension was then
centrifuged at 1500 x g (4000 rpm) for 10 minutes, and the supernatant discarded.
The powder was then washed with DI water and centrifuged 4 times to remove
lactic acid (an inert excipient in the i.v. solution). A final wash and centrifugation
with ethanol yielded a wet powder which was collected and dried in a vacuum
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desiccator. Ciprofloxacin yield was 90%. Survanta® was purchased from Abbot
Laboratories (Abbott Park, Illinois, USA). All the rest of the reagents were
purchased from Fisher Scientific (Hampton, NH, USA).
3.3.3.2.

Fabrication and characterization of liposomes
A lipid composition of 57% DPPC, 40% Cholesterol, and 3% DSPE-PEG-

NH2 conjugate was used. The lipids were dissolved in ethanol at 550 C and then
hydrated with a 400 mM ammonium sulfate solution (ethanol volume not
exceeding more than 10% of the final volume). The liposomes were made by
extruding the suspension of the hydrated dissolved lipids through a single 400
nm Whatman Nuclepore polycarbonate trach-etch membrane in a Lipex
Biomembranes extruder (Vancouver, British Columbia, Canada). The suspension
was then passed 7 times through the extruder at 50-54 0C and a pressure of
approximately 100 psi. The liposomes were characterized by DLS.
3.3.3.3.

Loading of liposomes with Ciprofloxacin
Ciprofloxacin was loaded into liposomes by the ammonium sulfate

gradient method [36]. Liposomes were diafiltered for 1-2 hours using 50 nm
cutoff tubings with the external phase of the liposomes being replaced with
saline (150 mM) at pH of ~5.3 in order to remove ethanol and unencapsulated
ammonium sulfate. For the remote loading procedure, Ciprofloxacin was
dissolved in saline (60 mg/ml) at pH 4.2 and 60ºC, and was gradually added (0.5
ml added every 3-5 minutes) to the liposomal suspension with the temperature

67

maintained at 60ºC. The loading was terminated after 1 hour by rapidly
dropping the temperature using an ice bath. The drop in temperature reduces the
permeability of the liposome bilayer thus preventing the transfer of species
across the bilayer and entrapping the loaded drug. Finally, the suspension was
separated from unencapsulated Ciprofloxacin by overnight dialysis against
saline solution (100 times volume of liposomes) at pH 5.3.
3.3.3.4.

Agglomeration

and

characterization

of

Ciprofloxacin

loaded

liposomes
Liposomes were agglomerated using DTSSP as the linker. The amount of
DTSSP used was a 10 – 20 fold molar excess over the number of PEG-NH2
groups on the outer leaflet of the liposomes. The pH of the reaction mixture was
maintained at ~ 7.4 (the optimal pH for DTSSP activity is in the 7-8.5 range). The
agglomerates were characterized for size by Fraunhofer diffraction.

3.3.3.5.

Visual analysis of agglomerates by negative stain electron
microscopy
The morphology of the agglomerates of DTSSP preparations was

examined by negative staining electron microscopy (EM). Copper grids coated
with colloid-ion-carbon and freshly glow discharged were used for sample
adsorption. Each grid was floated on a drop of sample for 5 min. Excess fluid
was removed by blotting with a filter paper, and the grid was washed for 2
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seconds on a drop of water, floated on a drop of 1% uranyl acetate for 15
seconds, and air dried for 2-5 minutes. All electron micrographs were taken with
a JEOL JEM1230 electron microscope operating at 80 kV and 56 µA beam current.

3.3.3.6.

Release studies
The release of Ciprofloxacin from agglomerates before and after cleavage

with cysteine was evaluated in vitro. 1 ml of Ciprofloxacin loaded agglomerates
(14 mM lipid) and 400 µl Survanta® was incubated at 37 °C in a dialysis bag
(100,000 MWCO) immersed in PBS at a pH of 7.4. The volume of the external
phase was 20 times that of the internal phase. Samples from the external phase
were taken and were assayed for Ciprofloxacin in the HPLC.
At different time points cysteine (8.7 mg/ml in total volume of dialysis
bag equivalent to 70 mM) was spiked into the dialysis bag, in an attempt to
trigger the release. To show that the modified release from the agglomerates was
due to cysteine and not due to any other factors, a separate study was done were
a volume of plain buffer equivalent to that of cysteine (50 µl) was introduced at
similar time points. At the end of the experiment the contents of the dialysis bag
were also assayed for Ciprofloxacin content.
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3.3.4.

In vivo cysteine triggered release studies

3.3.4.1.

Materials
DPPC was purchased from Genzyme Pharmaceuticals (Cambridge, MA,

USA). Cholesterol was purchased from Sigma-Aldrich (St. Louis, MO, USA).
DSPE-PEG-NH2 conjugate was purchased from Avanti Polar Lipids Inc
(Alabaster, AL, USA). The cross-linker DTSSP was purchased from Pierce
(Rockford, IL, USA). Fluorescently tagged lipid, N- (7-nitrobenz-2-oxa-1, 3diazol-4-yl)-1, 2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (NBD-PE)
was purchased from Invitrogen Corp. (Carlsbad, CA, USA). Ciprofloxacin (Bayer
Pharmaceutical Corp, West Haven, CT, USA) was purchased from a local
pharmacy as Cipro-I.V. solution and was purified as described in section 3.3.3.1.

3.3.4.2.

Animals
New Zealand White male rabbits (2.9 ± 0.5 kg) were purchased from

Myrtle Rabbitry (Thompson Station, TN, USA). Male Sprague Dawley rats (330 –
350 gm) were purchased from Harlan (Indianapolis, IN, USA). The use of
animals for this study was approved by the Center for Laboratory Animal
Medicine and Care (CLAMC) of UTHSC-Houston. Care and handling of the
animals was in accordance with all policies of the United States Department of
Agriculture (USDA) and U.S. Public Health Service (PHS).
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3.3.4.3.

Fabrication and characterization of liposomes

3.3.4.3.1.

Ciprofloxacin loaded liposomes

A lipid composition of 57% DPPC, 40% Cholesterol, and 3% DSPE-PEGNH2 conjugate was used. The liposomes were made by following the procedure
described in section 3.3.3.2. The liposomes were remotely loaded with
Ciprofloxacin following the same steps as in section 3.3.3.3.
3.3.4.3.2.

Liposomes with fluorescent labeled lipid

A lipid composition of DPPC:CHOL:DSPE-PEG-NH2:NBD-PE (56:40:3:1,
mol%) was used. After ethanol dissolution the lipids were hydrated with 150
mM NaCl solution (ethanol volume not exceeding more than 10% of the final
volume). The liposomes were made by extruding the suspension of the hydrated
lipids 7 times through a single 400 nm Whatman Nuclepore polycarbonate trachetch membrane in a Lipex Biomembranes extruder at 50-54 0C and a pressure of
approximately 100 psi. The liposomes were size characterized by DLS.

3.3.4.4.

Preparation and characterization of agglomerated liposomes
Liposomes with a lipid content of 50 mM were agglomerated using DTSSP

as the linker. The amount of DTSSP used for the agglomeration was a 10 - 20 fold
molar excess over the PEG-NH2 groups on the outer leaflet of the liposomes. The
cross-linking reaction was carried out at a pH of 7.4 (optimal for cross-linking
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activity of DTSSP) with constant stirring for 1.5 hours. The size distribution of
the agglomerates was determined using the Fraunhofer diffraction technique.

3.3.4.5.

Pharmacokinetic study in rabbits
Rabbits

were

anesthetized

by

a

subcutaneous

injection

of

ketamine/xylazine (40-50/5-10 mg/kg). The rabbits were maintained on 2%
isoflurane and O2 (1 lit/minute). The heart rate, temperature and O2 were
monitored periodically, and remained stable throughout the course of the
experiment.
The marginal ear vein was accessed via an i.v. catheter (24 G). The catheter
was taped to the ear. Using a laryngoscope, an endotracheal tube (size 3) was
inserted into the trachea, with a urinary catheter acting as a guide. Insertion into
trachea was confirmed with a stethoscope, by pumping air into the lungs. The
cuff of the endotracheal tube was filled with air to maintain the tube in the
trachea. Additionally, the tube was tied to the mouth to retain it in place.
The rabbit’s head was maintained in an upright position and drug
formulation was instilled into the lungs with a syringe. The formulation was
pushed down by forcing air into the lungs with the syringe several times. 2.2 to
2.8 ml of formulation (corresponding to Ciprofloxacin doses of 17 ± 1.6 mg/kg)
was instilled.
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Blood was drawn from the ear vein before (time 0) and after instillation of
drug formulation. Blood samples were centrifuged at 13,400 rpm for 15 minutes
to separate the plasma from cell components. The plasma was then diluted 1:4
times with methanol: phosphate buffer (9:1 v/v) to precipitate the proteins
present in the sample. The resulting suspension was then centrifuged at 13,400
rpm in a microcentrifuge for 15 minutes and the supernatant was assayed for
Ciprofloxacin content by HPLC. Standard curve for Ciprofloxacin was
determined by spiking known amounts of Ciprofloxacin in rabbit plasma. The
lowest detection limit by HPLC was 0.05 µg/ml.
The agglomerates made with the cross-linker DTSSP that were used in the
in vivo pharmacokinetic studies are termed as AVT2. Two sets of studies were
done with these agglomerates. In the first study the agglomerates were instilled
as described above, and their drug release was monitored.
In the second study, 1 ml cysteine (60 mg/ml) was introduced in to the
lungs 90 minutes after instillation of AVT2, to cleave the agglomerates and alter
the release of Ciprofloxacin into the blood. The rabbits recovered from anesthesia
and were returned to their cages after 6 hours. After 24 hours, the rabbits were
anesthetized and intubated again and cysteine solution was instilled again. Blood
was drawn at all the time points as described earlier.
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3.3.4.6.

Lipid assay of instilled formulations in rat lungs
To measure lipid elimination as a function of particle size and correlate it

to drug release, fluorescently tagged liposomes and agglomerates were instilled
in the lungs of rats and the residual fluorescence in lung tissue assayed over a 48
hour period.
Male Sprague Dawley rats were anesthetized with an intraperitoneal (i.p.)
injection of ketamine (80 mg/kg body wt.) and xylazine (10 mg/kg body wt.).
The rats were endotracheally intubated with a 16 G catheter. The endotracheal
tube was then connected to a ventilator and under forced ventilation; successful
intubation was confirmed if the chest of the rat expanded with the same
frequency as the ventilator.

200 µL of the liposomal and agglomerate

formulation (50 mM lipid content) with the fluorescent tagged lipids were
instilled into the lungs of the rats. The total lipid dosed was 4078.78 ± 506.07
µg/gm of lung wt. In a separate study 100 µL of cysteine (60mg/ml) was instilled
after 4 minutes from the instillation of the cleavable agglomerates (made with
DTSSP). At 2, 24, and 48 hours post-instillation of the liposomes and
agglomerates, the rats were euthanized with an overdose of pentobarbital (200
mg/kg) administered i.p. and the lungs were collected for the lipid assay.
The collected lungs were refrigerated and were processed within a few
hours of extraction. For the lipid extraction a modification of the method of
Matot et al. [48] was used. Briefly, the lungs were weighed, chopped and then
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homogenized in cold chloroform/methanol (2:1 vol.) mixture. The homogenized
tissue was filtered through Whatman filter paper no. 1. The collected filtrate was
then assayed for fluorescence in a SpectraMax GeminiXS spectrofluorometer
(Molecular Devices Corp, Sunnyvale, CA, USA) with filter settings of 463 nm
excitation and 530 nm emission wavelengths. (Calibration standards were made
by spiking known amounts of the tagged liposomes into the filtrate collected
from the lungs of untreated rats.) The fluorescence intensity associated with the
known lipid from the liposomes was used to determine the amount of lipid that
remained in the lungs after instillation of the liposomes and the agglomerates.

3.3.4.7.

Histology of rat lungs to assess inflammation
Male Sprague Dawley rats were anesthetized with an i.p. injection of

ketamine (80 mg/kg body wt.) and xylazine (10 mg/kg body wt.). The rats were
endotracheally intubated with a 16 G catheter following the same procedure as
described in section 3.3.4.6. In separate studies, formulations of (1) 20 µL of saline
(-ve control), (2) 40 µL of ConA solution (+ve control) containing 2.4 mg
ConA/kg body weight, (3) 20 µL of liposomes containing 0.41 mg of lipids/kg
body weight, and (4) 30 µL of AVT particles containing 1.74 mg of lipids/kg
body weight were instilled in the lungs of the rats. The rats were recovered from
anesthesia and returned to their cages.
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After 24 hours post-instillation the rats were euthanized with an overdose
of pentobarbital (200 mg/kg) administered via an i.p. injection and the lungs
were collected. The lungs were gently inflated with 10% neutral buffered
formalin until resistance was appreciated, and then immersed in formalin
overnight. The next day, the lungs were serially sectioned and submitted for
routine histological processing and paraffin embedding. Five micron-thick
sections were cut from each paraffin block and placed on glass slides, which
were stained with a standard hematoxylin-eosin (HE) stain. These slides were
reviewed by a practicing pathologist and evaluated semi-quantitatively for
changes of edema, inflammation and other histological abnormalities. The
inflammation triggered by the preparations was rank-ordered by the pathologist.

3.3.4.8.

Cytokine assay from rat lungs as a measure of inflammation
Male Sprague Dawley rats were anesthetized with an i.p. injection of

ketamine (80 mg/kg body wt.) and xylazine (10 mg/kg body wt.). The rats were
endotracheally intubated with a 16 G catheter following the same procedure as
described in section 3.3.4.6. In separate studies, formulations of (1) 250 µL of
liposomes (50 mM lipids; 34.7 mg lipid/ kg body wt.), (2) 250 µL AVT (50 mM
lipids; 34.7 mg lipid/ kg body wt.), (3) 250 µL of saline (-ve control), and (4) 50 µL
of ConA solution (+ve control) containing 4.1 mg ConA/kg body wt. were
instilled in the lungs of the rats. The Ciprofloxacin content of the liposomes and

76

AVT was 18 mg/ml. The rats were recovered from anesthesia and returned to
their cages.
After 48 hours post-instillation the rats were euthanized with an overdose
of pentobarbital (200 mg/kg) administered via an i.p. injection. The trachea was
exposed and a Teflon tubing with ~1.2 mm i.d. was inserted into the trachea and
held in place with a suture. An 18G needle adapter with a syringe was attached
to the tubing. The lungs were lavaged twice with 4 ml of sterile filtered (0.22
micron) PBS (10 mM phosphate, 150 mM NaCl). After instilling the lavage, the
chest and the abdomen of the rats were massaged for 30 seconds and then the
instilled fluid was aspirated. Total volume of the bronchoalveolar lavage (BAL)
collected was between 5-6 mls. The collected BAL was stored on ice till the
centrifugation step for ~ 3hrs. The BAL was centrifuged for 5 mins at 1000 g’s at
4 0C. The supernatant was collected and stored at -20 0C till the assay for
cytokines.
Four cytokines, viz. IL-2, IL-6, TNF-α, and IFN-γ were assayed
simultaneously in a multiplex panel using a Bio-Rad Bio-Plex cytokine assay kit
(Bio-Rad Laboratories Inc., Hercules, CA, USA). The collected samples were
thawed prior to assay. The instructions provided in the manual of the kit were
followed to prepare the standards and samples in the suspension plate. The plate
contents were read in a Bio-Rad Bio-Plex system powered by Luminex Xmap
technology.
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3.3.5.

In silico study of Ciprofloxacin pharmacokinetics of the 2nd
generation AVT
A mechanistic/deterministic compartmental model was employed as

already described in section 3.2.4 to analyze the Ciprofloxacin profiles obtained
from the pharmacokinetic studies.
In aaddition to the parameters already incorporated in the model, an
additional term (α’’) was introduced in the input bolus term of the AVT and the
lungs. This term takes into account the burst in release of drug from the AVT
particle at the time point when exogenous cysteine is introduced into the lungs.
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Chapter 4
Results and Discussions
4.1.

The 1st Generation of AVT (in vivo non-cleavable)
In this section the results of the efforts undertaken to fabricate the first

generation of agglomerated liposomes and test them in vitro and in vivo are
presented. The linker (DTBP) that was used to make the agglomerates is not
cleavable in vivo.

4.1.1.

In vitro experiments with blank liposomes

4.1.1.1.

Characterization of liposomes
Two sets of blank liposomes of 100 mM lipid content with 2% and 3%

PEG-NH2 conjugate in the bilayer were made. These were utilized to make
agglomerates under different conditions. The DLS results of the liposomes
extruded through the 400 nm polycarbonate membrane are shown in figure 14.
The DLS analysis suggested that the liposomes with 2% PEG-NH2 had a
size distribution between 180 – 440 nm with a mean diameter of 275.5 nm. The
liposomes with 3% PEG-NH2 showed a broader distribution between 165 – 765
nm with a mean diameter of 264.4 nm. These results are consistent with the
extrusion process of liposomes as reported by Sood [49]. The size of the
liposomes depends on a number of factors including lipid content, temperature,
pressure, buffer, pore size of the membrane, and number of passes.
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Figure 14. DLS results of blank liposomes with 2% PEG-NH2 and 3% PEG-NH2 used
for making agglomerates of DTBP.
Particles in the 1-5 nm range were also detected in DLS. These are most
likely to be micelles of the DSPE-PEG-NH2 conjugate that are formed during the
hydration process and are not incorporated in the lipid bilayer of the liposomes –
a normal occurrence observed with liposomes made with the PEG moiety
anchored to a lipid.

4.1.1.2.

Agglomeration of liposomes with DTBP
This preliminary study was undertaken to see how the amount of

reactants would affect the sizes of the agglomerates formed. In addition to this
the time-progression of the agglomeration process was also studied. Table 2 lists
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reaction conditions that were utilized for this study. The amount of the crosslinker DTBP used was in excess (molar basis) of the number of reacting groups
on the PEG conjugate present on the external surface of the liposomes.

Table 2. Reaction conditions that were used for making the agglomerates of blank
liposomes with DTBP cross-linker.
Mol% PEG-NH2

2

3

Lipid molarity of
liposomes (mM)

Molar excess of DTBP used over PEGNH2 present in the external bilayer of
the liposomes

10
20
50
10
20
50

25, 50, and 100 times
25, 50, and 100 times
25, 50, and 100 times
25, 50, and 100 times
25, 50, and 100 times
25, 50, and 100 times

As an example of the time progression of the agglomeration reaction,
figure 15 shows the Fraunhofer diffraction results of liposomes (2% PEG-NH2)
agglomerated with 50 times molar excess of DTBP (figure 15 a), and liposomes
(3% PEG-NH2) agglomerated with a 25 times molar excess of DTBP (figure 15 b).
The reactions were stopped by taking aliquots of the reaction mixture and
quenching them in a reservoir of Tris buffer (300 mM). During the initial time
points (5 mins and 25 mins) the sizes are broadly distributed from the submicron range (< 1 µm) to 100 µm. As the time of the reaction progressed the
particles in the sub-micron range were consumed resulting in bigger sizes as
observed by the disappearance of sub-micron sized liposomes. After 2 hours a
unimodal distribution was observed with a mode at 6.4 µm (figure 15a) and 11.1
µm (figure 15b). Particles bigger than 40 µm that are observed at 5 and 25
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minutes are no longer seen after 1 hour. The reason for this could be the
fragmentation of these bigger particles into the smaller size range possibly due to
the effects of stirring.
50 mM lipid, 2% PEG-NH2, 50 times DTBP. Stopped with Tris
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50 mM lipid, 3% PEG-NH2, 25 times DTBP. Stopped with Tris
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Figure 15. Time progression of agglomeration reaction of liposomes (50 mM lipid)
carrying (a) 2% PEG-NH2 with 50 times DTBP, and (b) 3% PEG-NH2 with 25 times
DTBP. The reactions were stopped with Tris and evaluated by Fraunhofer diffraction.
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Agglomerates (20 mM lipid), 3% PEG-NH2, after 3 days
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Figure 16. Size distributions of agglomerates obtained by Fraunhofer diffraction after
using different molar excess of DTBP linker over 3% PEG-NH2. Liposomes used were (a)
20 mM lipid, and (b) 50 mM lipid. The agglomerates were measured after 3 days from
the start of the reaction.
The agglomerates were analyzed after 3 days from the start of the
reaction. The reaction was not quenched with Tris after 2 hours, since the crosslinker loses its activity within a few hours. The sizes of the agglomerates

83

achieved with different amounts of linker for the same lipid molarity of the
liposomes were compared. As an example, figure 16 shows the size distribution
of the agglomerates of liposomes (3% PEG-NH2) having a lipid molarity of 20
mM (figure 16a) and 50 mM (figure 16b) achieved with the different amounts of
DTBP. The size distributions were unimodal with the sizes ranging from 3 – 40
µm. In case of the 20 mM lipids (figure 16a), the agglomerates had modes at 13.3,
11.1, and 8.4 µm made with 25, 50, and 100 times DTBP respectively. For the 50
mM lipids (figure 16b), the agglomerates had modes at 12, 9.2, and 7 µm made
with 25, 50, and 100 times DTBP respectively.
A common trend was observed wherein; the agglomerates formed with
less amount of linker were bigger than the agglomerates formed with higher
amounts. A possible explanation to this could be that the higher amount of linker
used reacts at a faster rate with the NH2 groups present on the liposomal surface.
Due to the higher bulk concentration of the reactants present at the start, the
initial collisions result in the formation of the agglomerates quickly. But as the
reaction sites on the liposomal surface start getting consumed by the smaller and
faster diffusing cross-linker molecules, no more sites are available for linking the
agglomerates formed that have a lower diffusion rate owing to their larger sizes.
In the case of the lower amounts of the linker used, the time for this saturation is
possibly slower resulting in more interaction between the activated and
inactivated sites that results in the formation of slightly bigger agglomerates.
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A similar trend was seen when liposomes with different molarities (the
lipid molarity is proportional to the number of liposomes of the same size) were
reacted with the same molar excess of DTBP. Figure 17 shows an example of the
same.
2%PEG-NH2, 100 times DTBP, after 3 days
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Figure 17. Size distributions of agglomerates obtained by Fraunhofer diffraction after
using liposomes with different lipid molarities with 100 molar excess of DTBP over (a)
2% PEG-NH2, and (b) 3% PEG-NH2 on liposomes. The agglomerates were measured
after 3 days from the start of the reaction.
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A lower lipid molarity of the liposomes resulted in larger agglomerates in
comparison to a higher lipid molarity. The agglomerates of liposomes with 2%
PEG-NH2 (figure 17a) had a unimodal distribution with modes at 3.35, 8.4, and
13.3 µm for 50, 20, and 10 mM of lipid. The agglomerates of liposomes with 3%
PEG-NH2 (figure 17b) also had a unimodal distribution with modes at 7, 10, and
16 µm for 50, 20, and 10 mM of lipid.
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Figure 18. Fraunhofer diffraction results showing the effect of pH on the
agglomeration of the liposomes.
During the agglomeration reaction it was observed, that the pH of the
mixture drifted from 8.15 to a lower pH of ~5.6 after addition of the linker. In the
previous results reported the pH was adjusted to 8.15 immediately after the
addition of the linker since the cross-linker is active at this point. To test if the
drift in pH affects the agglomeration reaction (ultimately affecting the size),
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liposomes (50 mM lipid) were reacted with DTBP (100 molar excess). The
Fraunhofer diffraction results shown in figure 18 clearly suggest that the pH
affects the extent of agglomeration. It was observed that the agglomeration was
incomplete when the pH was not adjusted as evidenced by the presence of submicron sized liposomes. This suggested that the activity of the cross-linker is lost
when the reaction is not carried in the optimal pH range.

4.1.2.

In vitro studies with Ciprofloxacin loaded liposomes

4.1.2.1.

Characterization of Ciprofloxacin loaded liposomes
The size distribution of Ciprofloxacin loaded liposomes is shown in figure

19. The liposomes, extruded through the 400 nm polycarbonate membrane, were
in the range of 180-195 nm.
After removal of the unencapsulated Ciprofloxacin, the concentration of
the encapsulated drug, determined by HPLC analysis, was 10.5 mg/mL,
representing 90% of the initial amount added during the loading procedure.
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Figure 19. Size distribution of Ciprofloxacin loaded liposomes.

4.1.2.2.

Agglomeration of Ciprofloxacin loaded liposomes with DTBP
Figure 20 shows a comparison of the size distribution (measured by

Fraunhofer diffraction) Ciprofloxacin loaded liposomes agglomerated with
DTBP at pH 5.2 (Prep I) and 8.5 (Prep II). In the case of Prep I, large agglomerates
exhibiting sizes between 4 – 60 µm and a mode at 21 µm were seen. A mode at <
1µm persists, suggesting that the parent liposomes have not been fully
agglomerated. In the case of Prep II, it was observed that the agglomerates
exhibited a very broad size distribution. These large agglomerates had sizes
between 1-160 µm and a mode at 34 µm. It was observed that the mode for
unagglomerated liposomes does not appear, implying that the majority of the
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parent liposomes have been agglomerated. These results of pH effects on
agglomeration are consistent with the studies done with blank liposomes.
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Figure 20. Fraunhofer diffraction results of agglomerates of Ciprofloxacin loaded
liposomes made at pH 5.2 and 8.5.

However, the agglomerates of Prep II showed a 70% leakage of the
encapsulated Ciprofloxacin even though the pH was brought back to 5.2 after the
end of the agglomeration reaction (3 hours). On the other hand, only 10% of the
encapsulated ciprofloxacin leaked out from the agglomerates of Prep I, since the
pH was maintained at 5.2, which was the pH throughout the remote loading
procedure. The leakage was tested by performing a dialysis experiment on the
agglomerates preparations and assaying the external phase of the dialysis bag for
Ciprofloxacin by HPLC.
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DTBP is cleavable by aggressive thiols like DTT (which is not suitable for
in vivo use). The Prep II agglomerates were cleaved with different amounts of
DTT at 37 0C. The results in figure 21 show that the extent of cleavage was more
when more DTT was used. This is evident by the increase in the fraction of
particles in the 1-20 µm, and fall in the fraction of agglomerates larger than 40
µm. However, the cleavage was not extensive, i.e. it did not result in the
formation of parent liposomes. It was anticipated that this cleavage of the
agglomerates would result in accelerated release of the drug.
Agglomerated Liposomes (Prep II)
Agglomerated Liposomes (Prep II) cleaved with 30 mg/mL
DTT
Agglomerated Liposomes (Prep II) cleaved with 60 mg/mL
DTT
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Figure 21. Size analysis of agglomerates of Ciprofloxacin loaded liposomes before and
after cleavage with 30 and 60 mg/ml of DTT at 37 0C.
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4.1.2.3.

Aerodynamic characterization of agglomerates
Figure 22 shows the results of the cascade impactor studies done with

liposomes agglomerated with DTBP, containing Ciprofloxacin to evaluate the
aerodynamic properties of the agglomerates. The results suggest that the
aerodynamic diameter of the agglomerates makes them highly respirable.
Approximately 60% of the agglomerates had aerodynamic diameters in the
respiratory range (between 1-5 µm). These diameters are clearly much lower than
the geometrical sizes of these agglomerates (Prep I) measured by Fraunhofer
diffraction (4-60 µm geometrical diameters). This data would be consistent with
either fragmentation of the agglomerates in the nebulizer or low density of the
porous agglomerates resulting in lowered aerodynamic diameters.
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Figure 22. Aerodynamic diameters of DTBP agglomerates (Prep I) determined by
cascade impaction.
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Approximately 25% of the nebulized Ciprofloxacin (encapsulated within
agglomerates) was collected and assayed in the impactor. The collection
efficiency was low possibly due to wall losses in the impactor and possible losses
while re-dissolving the material deposited on the plates, the elbow piece and the
after-filter of the impactor prior to the assay. It is also suspected that the low
efficiency may be contributed by the nebulizer, but could be improved in the
future by optimizing the choice of the nebulizer.
4.1.2.4.

Stability upon nebulization studies
The collection of the nebulisate was not very efficient. Only about 15% of

the nebulized Ciprofloxacin (in both the cases of liposomes as well as
agglomerates) was trapped in the saline. The remaining Ciprofloxacin was lost to
the walls of the collection flask and some to the atmosphere, carried by the air
stream exiting the flask. The material deposited on the walls was not included in
the analysis since it might have dried and hence disrupted the bilayer of the
liposomes, resulting in leakage. Leakage measured was only for the 15% of the
material that was collected in the collection medium. While it is possible that
some selection of the larger sizes did occur in the process, we tend to discount
this since the air velocities in the flask are very low and impaction distances to
both the liquid surface and the walls are about the same. It is therefore believed
that the 15% collection is representative of the overall nebulized material.
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It was expected that nebulization would cause a partial disruption of the
particles. This was reflected by an increase in size of the liposomes upon
nebulization as shown by the DLS result in figure 23.
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Figure 23. Effect of nebulization on the size of liposomes
One would expect similar disruption of the agglomerated particles. The
size distribution of agglomerates (Prep I) collected in saline upon nebulization as
analyzed by the Fraunhofer method, is shown in figure 24. It was observed that
the nebulization caused very little disruption of the agglomerates. The size
distribution of the nebulisate had a mode at 12.1 µm, whereas the agglomerates
exhibited a mode at 21 µm before nebulization. This disruption is suggested not
only by the shift of the peak of the agglomerates but also by the appearance of
more parent liposomes in the collected samples of nebulisate.
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Figure 24. Effect of nebulization on the size of agglomerated liposomes.
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Figure 25. Loss of encapsulated Ciprofloxacin from liposomes and agglomerates after
nebulization.
The nebulisate was assayed in order to measure the fraction of
Ciprofloxacin remaining encapsulated after nebulization for both parent
liposomes and the agglomerates. The results shown in figure 25 compare the loss
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of the encapsulated Ciprofloxacin from the liposomes and the agglomerates. The
results show a 41.74% loss of encapsulated Ciprofloxacin in the case of the
liposomes, but on the other hand the agglomerated formulation showed a
slightly lower loss of encapsulated drug. 36.71% of the encapsulated
Ciprofloxacin was lost from the agglomerates.
The size distribution and loss of drug results suggest that the
agglomerates were largely intact upon nebulization. It is possible that the
nebulization breaks the agglomerate bonds but not the liposomes themselves.
However, Wong et al [50] have shown that the force required to pull out a biotinPEG-lipid (similar to NH2-PEG-DSPE in this study) from a liposome is lower
than the force needed to break a streptavidin-biotin bond (analogous to the crosslinks in the study). Such pullout could result in leakage from the liposomes, such
as observed in this study. The nebulisate contained more liposomes and smaller
agglomerates than the pre-nebulized agglomerates supporting the fact that a
pullout of a small number of liposomes from the agglomerates took place. It is
therefore believed that the agglomerates remain largely intact during the
nebulization process.

4.1.2.5.

Release studies
Since each of the drug release experiments lasted for one or more days at

37 0C, a loss in the surfactant’s activity was expected [51]. A possible degradation
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of Ciprofloxacin was also expected due to the presence of proteolytic enzymes in
the surfactant.
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Figure 26. In vitro release of Ciprofloxacin from liposomes, and agglomerates (Prep I)
with and without cleavage with DTT. Arrows indicate time points at which agglomerates
were cleaved with DTT.
Figure 26 provides a comparison between the release profiles of
Ciprofloxacin from parent liposomes, agglomerates (Prep I), and agglomerates
cleaved with DTT. The agglomerates exhibited a similar initial burst as that of
the parent liposomes, however, the release reached a lower plateau much earlier
(~ 2 hours) as compared to almost 5 hours in the case of the liposomes. This
indicates that the structure of the agglomerates possibly plays a role in protecting
the liposomes in the inner core of the agglomerate from being exposed
immediately to the surfactant. The arrows indicate the time points when the DTT
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was added to the agglomerate and surfactant mixture. The introduction of the
cleaving agent resulted in more release of Ciprofloxacin from the agglomerates,
which reaches a higher plateau after sometime following the addition of DTT.
The addition of higher amounts of the DTT resulted in a relatively higher release
of Ciprofloxacin. This result suggests that the cross-links in the agglomerates are
cleaved by DTT, thus exposing the interior of the agglomerate structure to the
surfactant that consequently results in more release. This would be analogous to
the reduction in size observed by Fraunhofer analysis (figure 21) upon cleavage.
It was observed that after the last cleavage, the agglomerates released more drug
than the parent liposomes. A possible explanation to this could be that the
liposomes rearrange to form multi-lamellar vesicles (MLVs) in the presence of
lung surfactant. Such a rearrangement would be hindered in the case of the
agglomerated liposomes due to the cross-linkages.

4.1.3.

In vivo studies with Ciprofloxacin loaded liposomes

4.1.3.1.

Characterization of Ciprofloxacin loaded liposomes
The size of the liposomes, that were not agglomerated, was in the range of

160 to 400 nm with a mean of 330 nm. The size of liposomes that were
agglomerated later with DTBP to form AVT1, was in the range of 150 – 300 nm
with a mean of 260 nm.
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In the case of the liposomes that were not agglomerated, the concentration
of the encapsulated Ciprofloxacin was measured to be 26.4 mg/ml. This value
corresponds to 64% of the initial amount of Ciprofloxacin used during loading.
The concentration of encapsulated Ciprofloxacin of the liposomes used for
making the AVT1 particles was measured to be 26.6 mg/ml, corresponding to
80% encapsulation of the total amount of Ciprofloxacin used in the loading
procedure.

4.1.3.2.

Agglomeration of liposomes with DTBP
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Figure 27. Size distribution of agglomerates (AVT1) used in animal studies.
Figure 27 shows the geometric size distribution of the agglomerates AVT1
by Fraunhofer diffraction analysis. Less than 10% of the particles were in the
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submicron size range. The agglomerate population was broadly distributed from
1–140 µm with a mode at 31 µm. Upon performing a leakage study (by dialysis)
after the agglomeration, the amount of Ciprofloxacin that leaked from the
agglomerates was found to be less than 2%. The final encapsulated Ciprofloxacin
concentration of AVT1 was 17.8 mg/ml.
4.1.3.3.

Pharmacokinetic studies in rabbits
Figure 28 shows the blood levels of Ciprofloxacin after intratracheal

instillation of the free Ciprofloxacin, liposome-encapsulated Ciprofloxacin, and
AVT1 treatment. Each data point represents the mean and standard deviation of
the group (3 rabbits per group). The difference of the means between groups was
verified to be significant by variance analysis (Student’s t-test). A p-value less
than 0.05 was used to confirm significant differences at the 95% confidence level.
Table 3. Formulation of Ciprofloxacin instilled in the lungs of rabbits.
Ciprofloxacin Molarity of lipids
Drug:Lipid
Formulation
Dose (mg/kg)
(mM)
(molar)
21.07 ± 1.64
~120
0.66
Liposome
17.05 ± 0.44
~50
1.07
AVT1
15.4
NA
NA
Free Ciprofloxacin
The doses of the drug formulations instilled in the rabbits are tabulated in
table 3. It should be noted that Ciprofloxacin has a very low solubility at neutral
pH. Ciprofloxacin at a concentration of 21.9 mg/ml was instilled in the lungs in
this study to compare with the concentrations used in experiments involving
liposomes and the AVT particles. To keep Ciprofloxacin in solution at this
concentration, the pH of the formulation was maintained at ~3.1. The rabbit
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treated with the free Ciprofloxacin formulation showed signs of distress (heavy
panting) after instillation. When the lungs were observed post mortem, there
were signs of extensive injury highlighted by the darkening of the lung tissue.
Hence, no more rabbits were used to evaluate free ciprofloxacin. The lung injury
may be attributed to the high concentration of Ciprofloxacin that is in immediate
contact with the tissue and the low pH of the formulation. To the best of our
knowledge there are no studies reporting inflammation of the lungs or toxicity
effects due to administration of Ciprofloxacin to the lungs. No such signs of
damage were observed in the lungs of the rabbits that were used to evaluate the
liposomes and AVT particles.
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Figure 28. Pharmacokinetic data for the different formulation tested in rabbits. (n=1 for
the free Ciprofloxacin study, and n=3 for the other studies. Study with liposomes and free
Ciprofloxacin was done over 2 days. The AVT studies were done over 1 day).
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A burst in release was observed in the case of the free Ciprofloxacin
during the 1st hour, which then rapidly dropped to low values and eventually
went to zero at the end of 48 hours. Cmax in blood was measured to be 3.38

µg/ml. This rapid release can be attributed to the fact that Ciprofloxacin is in
direct contact with the tissue and is able to quickly diffuse out in the blood. An
assay of the lungs of the rabbit at the end of 48 hours indicated no Ciprofloxacin
remained in the lungs.
In the case of liposomes, and AVT1, though an initial burst in release of
drug was observed, it was much lower than that for free Ciprofloxacin.
However, the AVT1 particles and liposomes show that they are capable of
extended drug release in the blood. Cmax for the liposomal formulation was 0.34
± 0.06 µg/ml and this level of drug in the blood was maintained through the 48
hour period. Cmax for AVT1 was observed to be 1.53 ± 0.04 µg/ml with the level
gradually falling to 0.63 ± 0.08 µg/ml over 24 hours. Thus the entire curve for
AVT1 was higher than that for liposomes, indicating a much higher systemic
bioavailability. The lower initial release-burst for the liposomes and AVT1
particles is consistent with the fact that the Ciprofloxacin is encapsulated within
the particles and is not in direct contact with the lung environment. As the drug
leaks out of the particles, it is transported rapidly to the bloodstream, but at no
point is the free drug concentration in the lung high enough to cause a large
spike in the blood levels as observed in the free Ciprofloxacin case.
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Table 4. AUC0 – 24 for pharmacokinetic data of figure 28.
Formulation
Dose (mg/kg)
AUC0 - 24 (µg/ml.hr)
Liposome-encapsulated
8.02 ± 2.3
21.07 ± 1.64
Ciprofloxacin
19.8 ± 0.12
AVT1
17.05 ± 0.44
The areas under the concentration-time curves (AUC0 – 24) for AVT 1, and
liposomes for 24 hours were computed and are listed in table 4. The AUC’s
increase with the size of the particles, suggesting that the larger particles have an
improved systemic bioavailability in comparison to the smaller particles.

4.1.4.

In silico study of pharmacokinetics of 1st generation AVT
The input dose (known parameter) for the liposomes and AVT1 particles

are tabulated in table 5. The internal volume of the liposomes (VLips), and AVT1
(VAVT) that were instilled, were fixed at 2 ml. The surfactant volume of the
rabbits was assumed to be 1.8 ml. This volume of the pulmonary fluid was
estimated by comparing the known volume of the human pulmonary fluid (~35
mL) and correcting it with the body weight.
Table 5. Values of input dose used in the model.
Formulation
D (µg)
Liposome-encapsulated
69000
Ciprofloxacin
AVT1
40500

The plot of the model fitted to data for liposomes after the convergence
criteria were met is shown in figure 29. The parameters that the model estimates
to fit the data points are given in table 6.
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Figure 29. Model fit to data for pharmacokinetic studies done with liposomes.

Table 6. Unknown parameters estimated for pharmacokinetic study with liposomes
Parameter

Value (±sd)

95% confidence interval

α (µg)

549.54 (±361.2)

352.03

652.53

kLips (hr-1)

0.0024 (±0.003)

-0.006

0.01

kL0 (hr-1)

1.67 (±1.33)

-2.01

5.35

kL (hr-1)

0.012 (±0.013)

-0.023

0.047

Upon instillation of the liposomes, the value of α indicated that 0.8% of
the encapsulated drug leaked from the particles and appeared free in the lungs
due to fragmentation of the particles. The first order release rate constant from
the liposomes (kLips) was estimated to be very low. The elimination rate constant
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of the drug from the lung (kL0) was estimated by the model to be 2 orders of
magnitude larger than the rate constant (kL) that transfers drug from the lungs
into the blood.

AVT1

1.80

Experiment

1.60

Simulation

1.40

Ciprofloxacin in
blood (µg/ml)

1.20
1.00
0.80
0.60
0.40
0.20
0.00

0

5

10
15
Time (hours)

20

25

30

Figure 30. Model fit to data for pharmacokinetic studies done with AVT1.
The simulation fitted to the data for the AVT1 particles is shown in figure
30 with the unknown parameters estimated for the study are given in table 7. The
value of ‘α’ that was estimated represented 8% of the initial drug instilled in the
lungs. The value of α is higher than that for the liposomal treatment suggesting
that after the instillation, the AVT are fragmented to a higher extent than the
liposomes resulting in a higher drug leakage into the lung compartment (with
subsequent release into the blood compartment). The fragmentation in turn may
be caused due to the significant motion of the lungs during breathing, applying
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shear to the AVT particles. This is not the case when it comes to the liposomes as
they are compact and resist to a greater extent the shearing action of the lungs
during breathing.
Table 7. Unknown parameters estimated for pharmacokinetic study with AVT1.
Parameter

Value (±sd)

95% confidence interval

α (µg)

3133.12 (±381.64)

2269.8

3996.44

kAVT (hr-1)

0.035 (±0.006)

0.023

0.048

kL0 (hr-1)

0.881 (±0.204)

0.72

2.14

kL (hr-1)

0.006 (±0.001)

0.004

0.008

The estimates suggest that AVT1 have a better release rate than the
liposomes (kAVT > kLips). This is also supported by the higher levels of drug that is
maintained in the blood. The marginally lower clearance rate constant of AVT1
in comparison to the liposomes (kL0) suggests that the amount of drug that is
cleared from the lungs is mostly free drug in the case of the AVT1 plus drug that
may be associated with the fragments that may be formed due to the shearing
nature of the lungs. In the case of the liposomes, the drug cleared is free drug
plus drug encapsulated within the liposomes that may be cleared by the
macrophages. The action of the macrophages is assumed to be lower in the case
of the AVT1 due to their large size, with only the fragmented particles being
taken up if they are within the size range for macrophage activity.
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4.2.

The 2nd generation of AVT (in vivo cleavable)
The commercially available cross-linker DTSSP was identified to be

cleavable by cysteine (acceptable for in vivo use). In this section the results of the
studies that were undertaken in vitro to show size reduction and drug release
upon cleavage are reported. Additionally the in vivo studies that were
undertaken to suggest modulated release capabilities of the agglomerates made
with this linker are also discussed.

4.2.1.

In vitro studies with blank liposomes

4.2.1.1.

Characterization of liposomes
The size of the liposomes extruded through the 400 nm polycarbonate

membrane, as measured by DLS was in the range of 180-340 nm with a mean
diameter at 244 nm. These were consistent with the sizes achieved during the
numerous undertakings for fabricating the liposomes.
4.2.1.2.

Agglomeration of liposomes with DTSSP
Agglomerates of liposomes that were made with DTSSP were incubated

with different amounts of cysteine at 37 0C in order to see if cleavage was
possible. The sizes of the agglomerates were analyzed by the Fraunhofer
diffraction method, before and after cleavage. The results of these studies are
shown in figure 31. The agglomerates of liposomes (50 mM lipid) made with 20
fold molar excess of DTSSP had sizes between 3.5 – 95 µm with a mode at 19.4
µm.
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Figure 31. Fraunhofer diffraction analysis of liposomes agglomerated with DTSSP, and
subsequent cleavage with cysteine at 37 0C. Agglomerates with (a) 20 mM lipid, and (b)
1.25 mM lipid.
These agglomerates were then cleaved with different amounts of cysteine
at lipid molarities of 20 mM (figure 31a) and 1.25 mM (figure 31b). It was
observed that the reduction in the size of the agglomerates was proportional to
the amount of cysteine that was used. This is evident by a shift in the size
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distributions to the smaller sizes with an increase in the fraction of particles in
the 4-16 µm, and a fall in the fraction of agglomerates larger than 30 µm.
However, the cleavage was not extensive, i.e. it did not result in the formation of
parent liposomes. It was anticipated that this cleavage of the agglomerates would
result in accelerated release of the drug.

4.2.2.

In vitro studies with carboxyfluorescein (CF) loaded liposomes

4.2.2.1.

Characterization of liposomes
The liposomes encapsulating 5 mM CF that were extruded through 400

nm polycarbonate membrane had a size distribution between 170-350 nm with a
mean diameter of 241 nm. These sizes were consistent with those achieved with
the extrusion process.
4.2.2.2.

Agglomeration of liposomes with DTSSP
The liposomes encapsulating CF were agglomerated with DTSSP and

were sized by Fraunhofer diffraction analysis. The size distributions are shown
in figure 32. The agglomerates were distributed from 1-90 µm.
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Figure 32. Fraunhofer analysis of agglomerates of liposomes encapsulating CF.
These agglomerates were used for visual analysis of the structure of the
agglomerate by confocal microscopy.
4.2.2.3.

Visual analysis of agglomerates by Confocal microscopy
A montage of the slices of the one of the agglomerates that was imaged is

shown in figure 33. The Z-stack for the slices was set at 0.5 µm. The stack size of
the image was 36.6 µm x 36.6 µm x 7.5 µm. The pixel resolution of each slice was
512 x 512. The size of the agglomerate seen here is between 3-8 µm. The slices
through the agglomerate indicate the presence of compact domains (bright areas)
and porous domains (dark areas within the agglomerate). This heterogeneity in
the structure can be attributed to two things that may be happening during the
reaction: (1) The initial fast reaction leads to the formation of smaller compact
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agglomerates of the liposomes, (2) the activated ligands on the liposomes present
at the outer boundary of these compact agglomerates then form cross-links with
the un-activated ligands on other agglomerates to form the larger agglomerate.
0 µm
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Figure 33. Slices of confocal image of an agglomerate encapsulating carboxyfluorescein.
Data at top right corner of each image is the Z-stack height, with Z-stack slices taken
every 0.5 µm.
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The image slices that were obtained were then processed and analyzed
with ImageJ (NIH) to determine the void area fraction of the agglomerate.
Briefly, each slice was converted to an 8 – bit grayscale image. A binary threshold
was then applied to the resulting image. Using the Wand tracing tool in ImageJ,
the boundary of the resulting agglomerate structure was determined. The area
fraction of this bounded image was then determined using the built-in macro
‘MeasureAreaFraction’. The void fraction of the agglomerate was determined to
be 5-10% of the total area of the agglomerate.

4.2.3.

In vitro studies with Ciprofloxacin loaded liposomes

4.2.3.1.

Characterization of Ciprofloxacin loaded liposomes
The sizes of the Ciprofloxacin loaded liposomes as determined by DLS

were in the range of 140 – 350 nm with a mean at 210 nm. This was consistent
with the sizes obtained after extrusion through the 400 nm polycarbonate
membrane. After removal of the unencapsulated Ciprofloxacin by dialysis the
final concentration of Ciprofloxacin was found to be 21 mg/ml, which
represented 80% of the initial drug used during the loading.
The agglomerates of these liposomes made with the cysteine cleavable
linker DTSSP were used for both in vitro and in vivo studies.
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4.2.3.2.

Agglomeration of Ciprofloxacin loaded liposomes with DTSSP
The sizes of the agglomerates as determined by the Fraunhofer diffraction

technique are shown in figure 34. The agglomerates had a size distribution
between 2 – 100 µm with a mode at 5.5 µm. These agglomerates were used in
vitro drug release experiments.

4.5
DTSSP Agglomerates

4
3.5

%Frequency

3
2.5
2

1.5
1
0.5
0
0.1

1

Size (µm) 10

100

1000

Figure 34. Size distribution of agglomerates of liposomes encapsulating Ciprofloxacin.

4.2.3.3.

Visual analysis of agglomerates by negative stain electron
microscopy
The agglomerates of DTSSP made in the previous section were visualized

by negative stain electron microscopy. Figure 35 shows the negative stain
electron microscope (EM) images of liposomes and AVT particles encapsulating
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Ciprofloxacin. Figure 35a shows the EM image of the parent liposomes with
diameters around 200 nm. Since the length of the PEG anchor (~7 nm) is very
small compared to the size of the liposome, linked liposomes are in close
proximity as shown in Figures 35b–d.

a

b

c

d

Figure 35. Negative stain electron microscope images (1% uranyl acetate) taken on a
JEOL JEM 1230. (a) liposomes at 10 K magnification, scale bar 0.2 µm; (b) agglomerate
at 10 K magnification, scale bar 0.2 µm; (c) agglomerate at 2 K magnification, scale bar 2
µm; (d) agglomerate at 4 K magnification, scale bar 1 µm.
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The agglomerates clearly consisted of clusters of cross-linked liposomes
incorporating high amounts of the negative stain suggesting high accessibility of
the aqueous phase to the interior of the agglomerate structure. A heterogeneous
structure can be seen that includes highly porous as well as compact domains
within the agglomerate. As the compact structures were nucleated rapidly,
diffusion-limitations dominated during the agglomeration reaction, resulting in
the formation of porous structures of the compact “nuclei”. Similar structures are
expected for all the agglomerates formed, since the reaction conditions for each
were very similar. One therefore expects that drug release properties of each of
the agglomerates would also be very similar to each other.
4.2.3.4.

Release studies

The results of the in vitro release experiments undertaken to show
modulated release of the drug from the agglomerates after treatment with
cysteine are shown in figure 36. To show that the modified release from the
agglomerates was due to cysteine alone and not due to any other factors, a third
study was done were a volume of plain buffer equivalent to that of cysteine (50
µl) was introduced at similar time points. Upon the introduction of cysteine into
the dialysis bag accelerated release of drug into the external phase was observed.
The results suggested as expected that the increased release was due to cysteine
addition and not due to other factors. The overall release from the cleaved
agglomerates was higher than from the agglomerates that were not cleaved.
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Figure 36. In vitro release profiles from uncleaved agglomerates, agglomerates that were
repeatedly cleaved with cysteine, and agglomerates treated with plain buffer. (Arrows
indicate time points at which 50 µl of either buffer or cysteine containing buffer is
introduced.)

This result suggests that the cross-links in the agglomerates are cleaved by
cysteine, thus exposing the interior of the agglomerate structure to the surfactant
that consequently results in more release.

This would be analogous to the

reduction in size of the DTSSP agglomerates observed by Fraunhofer analysis
(figure 31) upon cleavage with cysteine.
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4.2.4.

In vivo cysteine triggered release studies

4.2.4.1.

Characterization of liposomes
The size of the liposomes encapsulating Ciprofloxacin was in the range of

140 – 350 nm with a mean at 210 nm. The liposomes incorporating fluorescent
tagged lipid (used in the lipid assay from the lungs) were in the range of 177 –
460 nm with a mean at 290 nm.
4.2.4.2.

Agglomeration of liposomes with DTSSP
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Figure 37. Particle size distribution, by Fraunhofer Diffraction, of the agglomerates used
in the pharmacokinetic and lipid assay studies.
The particle size distributions, by Fraunhofer Diffraction, of AVT2 (DTSSP
agglomerates of liposomes encapsulating Ciprofloxacin used in vivo) that were

116

used for the pharmacokinetic studies, and that of the agglomerates used for the
lipid assay studies, are shown in figure 37. The agglomerate populations for
AVT2 were distributed from 2 –120 µm with a mode at 11 µm.
The agglomerates of DTSSP that were used for the lipid assay studies
showed a bimodal distribution from 1 – 125 µm, with one mode at 5 µm and the
second one at 44 µm.
4.2.4.3.

Pharmacokinetic studies in rabbits
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Figure 38. Pharmacokinetic data of AVT2 particles, with and without cysteine
treatment. Arrows indicate time points when 1 ml cysteine (60 mg/ml) was instilled. n=3
animals.
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Figure 38 shows the blood levels of Ciprofloxacin after intratracheal
instillation of the AVT 2, and AVT 2 + cysteine treatment. Each data point
represents the mean and standard deviation of the group (3 rabbits per group).
The difference of the means between groups was verified to be significant by
variance analysis (Student’s t-test). A p-value less than 0.05 was used to confirm
significant differences at the 95% confidence level. The dose of the AVT2 that
was instilled in the rabbits for the two studies is shown in table 8.

Table 8. Dose of AVT2 instilled in the lungs of rabbits.
Ciprofloxacin Molarity of lipids
Formulation
Dose (mg/kg)
(mM)
18.31±0.62
~50
AVT 2

Drug:Lipid
(molar)
1.07

The AVT2 exhibited an initial burst in release, but the levels were lower
compared to the study done with the free Ciprofloxacin (section 4.1.3.3). The
AVT 2 particles exhibited a Cmax of 0.8 ± 0.07 µg/ml followed by a gradual drop
to 0.24 ± 0.04 µg/ml in 24 hours.
After instillation of cysteine at 90 minutes into the lungs of the rabbits an
elevation in release rate was observed. The Cmax attained due to cysteine
instillation was 1.27 ± 0.22 µg/ml. The blood levels of drug in animals treated
with AVT2 and then with cysteine are significantly different (p < 0.05) from those
for the same formulation with no cysteine treatment. The systemic bioavailability
of the AVT2 particles is clearly improved after cysteine instillation as indicated
by the increase in the AUC.
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A 40% increase in total release (as measured by the area under the curve,
AUC) was caused by the cysteine instillation. After 24 hours a repeat cysteine
instillation resulted in further triggered release. However, smaller drug amounts
were released consistent with overall lower residual drug content in the particles
at this extended time post administration. The triggered release due to cysteine
addition may be attributed to the cleaving of the disulfide linkages on the DTSSP
that links two liposomes. This breakage would result in the rupture of the
structure of the microparticle resulting in accelerated drug release.

1.8

Liposomes

AVT 1

AVT 2

AVT 2 + cysteine

1.6
1.4

Ciprofloxacin in
blood (µg/mL)

1.2
1
0.8
0.6
0.4
0.2
0
0

180 360 540 720 900 1080 1260 1440 1620 1800 1980 2160 2340 2520 2700 2880
Time (min)

Figure 39. Comparison of the pharmacokinetics of liposomes, AVT1, AVT2, and AVT2
followed by cysteine. Study with liposomes was done over 2 days. The AVT studies were
done over 1 day. n=3 animals.
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A comparison of the pharmacokinetics of the AVT2 particles with the
previous treatment of liposomes and AVT1 (section 4.1.3.3) is shown in figure 39.
The differences in size and the nanostructure of the particles affect the release
properties of the microparticle formed. On the basis of size AVT1 > AVT2 >
Liposomes. A compact structure of the agglomerate would represent a high
concentration of drug-bearing nanoparticles, which may not promote diffusive
transport. On the other hand, a more porous, open structure would represent a
lower concentration of drug-bearing particles, but a higher diffusive transport
rate. Also, due to the dynamic nature of the lungs, large and loose agglomerates
maybe more susceptible to rupture and consequent increase in drug release in
comparison to smaller compact agglomerates. This would mean more drug being
released into the systemic circulation. As seen in figure 39 AVT1 show higher
release of drug into the blood as compared to AVT2.

Table 9. AUC0 – 24 for each of the formulations tested.
Formulation

Dose (mg/kg)

AUC0 - 24 (µg/ml.hr)

Liposome-encapsulated
Ciprofloxacin

21.07 ± 1.64

8.02 ± 2.3

AVT 1

17.05 ± 0.44

19.8 ± 0.12

AVT 2

18.31 ± 0.62

10.45 ± 0.92

AVT 2 + cysteine

18.56 ± 0.54

14.51 ± 2.3

A comparison of the areas under the concentration-time curves (AUC0 – 24)
for AVT1, AVT2, AVT2 + cysteine, and liposomes, is shown in Table 9. The
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AUC’s increase with the size of the particles, suggesting that the larger particles
have an improved systemic bioavailability in comparison to the smaller particles.
4.2.4.4.

Lipid assay of instilled formulations in rat lungs
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Figure 40. Percentage of original dosed lipid remaining in the lungs on the basis of
fluorescence assay of the tagged lipid. n = 3 animals.

The measurement of lipid retained in the lungs indicated that there is no
significant difference between liposomes and agglomerates (figure 40). Further,
there is no systematic change in lipid levels during the 48 hour observation
period; 50 – 60% of the initial amount of lipids dosed is observed in the lungs at
all times. This is an offset of the experiment, due to losses during the processing
of lungs tissue before the assay. This result is similar to those of Webb et al [52]
who showed that after instillation of liposomes the amount of lipid observed in
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the lungs during 24 hours post administration was between 76 – 106% of initial
lipid dose suggesting that the lipids are not transported into the circulation. We
therefore believe that the total lipid (as particles) is remaining in the lungs for the
entire time of the experiment (48 hours), and that drug release from the particles
into the lungs then results in the transport of free drug into the systemic
circulation.
4.2.4.5.

Histology of rat lungs to assess inflammation

B

A

D

C

Figure 41. Histological analysis of hematoxylin-eosin stained lung tissue 24 hrs after
treatment (original magnification 100X); (A) saline-treated animals; (B) ConA-treated
rats; (C) liposome-treated animals; (D) AVT-treated animals. n = 2 animals
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A qualitative analysis of inflammation after instillation of the formulations
was done by histology. The HE stained sections of lung tissue were rank ordered
by a practicing Pathologist and are shown in figure 41.
In saline-treated rats (figure 41A), the lung tissue was observed to be
almost entirely normal. The ConA-treated (Concanavalin A) rats (figure 41B)
demonstrated extensive pneumonic changes in their lungs. A bronchiole and
adjacent

alveoli showed mixed inflammatory

cell infiltrates including

neutrophils and lymphocytes, accompanied by alveolar hemorrhage. In the
liposome-treated animals (figure 41C), patchy lymphocytic infiltrates were noted
around a bronchiole, blood vessels, and in the interstitium in the left upper lobe
of one of the rats receiving the liposomes. In AVT-treated animals (figure 41 D),
the majority of the lung tissue in the rats had a normal appearance. This
suggested that the AVT particles do not elicit a major inflammatory response,
and are therefore safe to be used in therapy. The reason for this may be
attributed in part to the large size of the AVT particles and also the fact that they
are composed of phospholipids, which is a major component of the lung
surfactant.
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4.2.4.6.

Cytokine assay from rat lungs as a measure of inflammation
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Figure 42. Levels of cytokines detected 48 hours after the different treatments (n = 3
animals)
The levels of cytokines that were assayed for the different treatments are
as shown in figure 42. As expected for the ConA treatment the levels of the 4
cytokines that were assayed were higher than the levels of the respective
cytokines for the other treatments. The IFN-γ levels were detected only for the
ConA treatment. The IL-2 levels for the liposomal and AVT treatment were
comparable to the saline treatment. The TNF-α levels of the liposomes and AVT
particles were approximately 5 times the levels of the saline treatment. No IL-6
was detected in the saline treated animals. The levels of the respective cytokines
were similar for the liposomal and AVT treatment. Some level of inflammation
was expected due to the instillation of foreign material into the lungs; however
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these levels are much lower than the ConA treatment, which suggest that these
treatments do not elicit a huge inflammatory response and support the findings
from the histological analysis.

4.2.5.

In silico study of Ciprofloxacin pharmacokinetics
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Figure 43. Model fit to experimental data for (a) AVT2, and (b) AVT2 + Cysteine.
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The results of the model that was fitted by the SAAM II software to the
experimental pharmacokinetic data (section 4.2.4.3) for the AVT2 particle
treatment are shown in figure 43. The input dose ‘D’ (known parameter) for the
AVT2 particles was 46783 µg. The unknown parameters that were estimated for
the AVT2 treatment (figure 43a) are shown in table 10.
Table 10. Unknown parameters estimated for pharmacokinetic study with AVT2.
Parameter

Value (±sd)

95% confidence interval

α (µg)

1116.27 (±36.9 )

1035.77

1196.76

kAVT (hr-1)

0.0027 (±0. 002)

-0.001

0.006

kL0 (hr-1)

0.42 (±0.16)

0.12

0.91

kL (hr-1)

0.006 (±0.000)

0.005

0.008

The value of α that was estimated represents 2.4% of the initial amount of
drug dosed. A comparison of the kAVT values of AVT2 with the liposomes
(section 4.1.4) suggests that the diffusion rate of the drug is similar. The
elimination rate constant (kL0) is lower than the liposomes, suggesting that in
addition to the free drug being cleared, the clearance due to macrophages is
lower.
For the AVT2 followed by cysteine treatment the values of α, kAVT, and kL
were fixed. Due to instillation of cysteine, a cleavage of the linkages between the
liposomes was expected and hence a leakage of drug (represented by α’’) was
assumed due to the fragmentation in the structure of the microparticle. Also,
because of the cleavage and fragmentation the elimination of the AVT2 would be
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different due to the changes in sizes; hence kL0 was also estimated assuming that
it would be different from the treatment with only AVT2. The values of these
estimated parameters are shown in table 11.
Table 11. Unknown parameters estimated for pharmacokinetic study with AVT2 +
cysteine.
Parameter

Value (±sd)

95% confidence interval

α’’ at 90 minutes (μg)

2240.92 (±530.5 )

1103.12

3378.72

α’’ at 24 hrs and 35
minutes (μg)

469.1 (±400.53)

-390.04

1328.21

kL0 (hr-1)

0.853 (±0.231)

0.356

1.349

The value of α’’ at 90 minutes was estimated to be 10% of the drug that
remained in the lungs at 90 minutes. The value of α’’ at 24 hours and 35 minutes
was estimated to be 2.3% of the drug that remained in the lungs at that time
point. The model estimated that the elimination of drug from the lungs (kL0) was
higher in the case of the treatment with agglomerates followed by cysteine. This
suggested that the clearance of the drug (due to lymphatic or macrophage
clearance) is increased after the cleavage.
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Chapter 5
Conclusions and Future work
5.1.

Conclusions
In the preliminary studies that were undertaken [38], the use of different

cross-linkers was investigated in order to form agglomerates of nano-sized
liposomes. Keeping in mind the modulation of release of drug from these
microparticles after instillation in the lungs; DTBP, a thiol cleavable linker was
extensively studied. Large microparticles were fabricated exhibiting diameters of
10’s of microns. The sizes of the agglomerates could be controlled by the
stoichiometry of the reaction (e.g. by changing either the lipid molarity of the
parent liposomes or the amount of the linker), and the conditions of the reaction
(e.g. pH). By following different agglomeration protocols agglomerates of
different size distributions were achieved with geometrical diameters ranging
from 2-140 μm.
The aerodynamic properties of there large agglomerated particles were
determined by cascade impaction study, which is a recommended USP method
that is used by industry to test the aerodynamic properties of drug particles that
are used as an inhalation therapy. It was observed that the large agglomerates
had aerodynamic diameters in the respiratory range (1-5 μm). The size
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characterization upon nebulization showed that the agglomerates were largely
intact and only a small fraction of them were disrupted. Additionally, the
nebulized agglomerates retained most of the encapsulated drug. These results
suggested that the agglomerates remained intact during the nebulization process.
The in vitro release experiments from the agglomerates of the 1st
generation showed that by the introduction of a cleaving agent that breaks the
linkages between the liposomes within an agglomerate modulation in the release
of the drug could be achieved. However, the cleaving agent used was DTT,
which is not a suitable candidate for use in vivo.
In order to bring about post-administration modulation of drug release in
vivo, cross-linkers that can be cleaved in vivo were researched. DTSSP a
commercially available linker was found to be cleavable by cysteine (acceptable
for in vivo use). The in vitro experiments carried out with this linker suggested
that the agglomerates of liposomes made with this linker are cleavable by
cysteine. In vitro release experiments suggested that a modulation in release
could be achieved by the cleavage of the cross-links with cysteine.
An analysis of the agglomerates by confocal microscopy and negative
staining electron microscopy suggested a heterogeneous structure that included
highly porous as well as compact domains within the agglomerate. As the
compact structures were nucleated rapidly, diffusion-limitations dominated
during the agglomeration reaction, resulting in the formation of porous
structures of the compact “nuclei”. The void fraction within the agglomerates
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was estimated to be between 5-10% of the entire agglomerate. This porous
property of the agglomerate also supports the lower aerodynamic diameters (by
cascade impaction) exhibited by the agglomerates with large geometric
diameters.
The in vivo experiments showed that, when the AVT particles of DTSSP
were cleaved by cysteine, a triggered release of Ciprofloxacin was achieved. Both
the AVT particles and unagglomerated liposomes appear to remain in the lung
for at least 48 hours after administration. The mechanism by which Ciprofloxacin
is delivered to the blood therefore appears to be (1) a release of Ciprofloxacin
from the particles into the lung fluid, followed by (2) transport of the free
Ciprofloxacin into the bloodstream. Specifically, the transport of encapsulated
Ciprofloxacin into the blood is not suggested by our results. In contrast, previous
work by Wong et al. [53] showed that liposomal Ciprofloxacin was more
effective than free Ciprofloxacin against intracellular pathogens such as F.
tularensis, suggesting that liposomal drug was possibly transported intact into
macrophages. However, the liposomal formulations used by Wong were
substantially different from those used in this work, and it is possible that
changes in the bilayer composition affect the route of clearance from the lung.
AVT particles also exhibited higher bioavailability than the liposomes, as
indicated by the higher AUC for the AVT particles. This is somewhat
counterintuitive, since one expects the higher surface area of the parent
liposomes to result in higher release rates. However, this phenomenon has been
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previously observed in vitro, and it is believed that the larger AVT particles,
being subjected to larger shear forces in the lung, were disrupted more easily
than the smaller liposomes. Thus, AVT particles are expected to have two
mechanisms for drug release (1) diffusion of the drug out of the liposomes
themselves and (2) bulk leakage due to bilayer disruption. This mechanism is
consistent with the repeated observation that AVT particles have higher
bioavailabilities than liposomes.
The two AVT formulations tested in vivo also had somewhat different
bioavailabilities. While the reasons for this are yet unclear, they are probably
related to the different size distributions of the two AVT particle formulations.
The in vivo non-cleavable formulation - AVT1, had larger particles than the in
vivo cleavable AVT2, and hence was prone to a larger extent of disruption and
subsequent drug leakage, due to the shearing forces of the lung than the smaller
AVT2. Thus, AVT1 had a higher release and bioavailability.
Cleavage of the links in AVT2 by the administration of exogenous cysteine
caused an immediate increase in Ciprofloxacin release. Further, the release rate
appears to remain at this elevated level, reflected by an increased blood
concentration of Ciprofloxacin at subsequent times. The cumulative release,
measured by the AUC, is also higher for the cleaved formulation, consistent with
this overall increased release rate.
The toxicity studies that were done by histology and cytokine analysis
indicate that the AVT particles did not elicit a major inflammatory response. This
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was supported by lower infiltration of neutrophils and lymphocytes. The
cytokine levels were low as well. These low levels of inflammation can be
attributed to the phospholipid composition of the particles which is similar to
that of the surfactant that lines the lungs.
This study is the first demonstration of in vivo modulated release of drug
in the lungs. Though the formulations were instilled into the lungs of animals,
the aerodynamic characteristics of the particles suggest that the platform that has
been developed holds great promise for delivering drugs into the lungs of
humans.

5.2.

Future work
The technology in its present form is capable of being delivered by

nebulizers. An optimal nebulizer for delivering these agglomerates with minimal
structural damage needs to be evaluated. This technology can also be applied to
MDIs and DPIs, but issues of drying the particles need to be kept in mind.
Drying the liposomes would destroy the integrity of the bilayer, however, they
can be protected with sugars [54-56] and then dried. Sugar protection is known
to retain a layer of water in close proximity to the bilayer, thus stabilizing it.
Though inflammation studies were performed, the cellular uptake of the
AVT particles needs to be investigated. It would be particularly interesting to see
if macrophages are capable of engulfing these large agglomerates. Only a single
time point was used for the evaluation of inflammation. However, the time
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evolution of inflammation needs to be evaluated to see if the levels remain low at
different time points.
Since, the platform could be used over a prolonged time period for
treatment; chronic toxicity studies need to be undertaken. Owing to the fact that
the acute toxicity studies showed minimal inflammation, lower levels of chronic
toxicity are expected.

5.3.

Clinical perspectives of the work
The AVT is a platform technology and can, therefore, be used to deliver

therapeutic molecules to treat local lung diseases and also systemic diseases. In
this work it was sought to see if triggered/modulated release of drug is possible
from carriers that are administered to lungs. It was envisioned that repeated
doses of the drug formulation could be replaced with a single dose. This is
particularly helpful in delivering drugs that are not easily portable, and also
where the concerns of excipient buildup in the lungs due to repeated dosing can
be an issue. Current technologies do provide controlled release of drug, but if the
need arises for more drug to be delivered an additional dose of the formulation
would be required. This work showed that modulation can be achieved from the
AVT particles by the introduction of a second agent that is easily portable and
stable.
The present work with Ciprofloxacin suggests that the technology can be
used both as a prophylactic as well as a treatment, with lower drug dosages.
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Similarly, other anti-infective drugs for treating both local as well as systemic
diseases can be used. This could prove to be useful in biologically hot
environments like hospitals, where noscomial infections can be prevented. This
technology can also prove helpful by providing protection in a military combat
situation dealing with the use of biological agents, for example weaponized
aerosol form of anthrax.
This work has important implications in developing particles that are
sensitive to the product of a disease, and are thus capable of modulating drug
release without the need for administration of additional agents. For example, if
insulin release were to be triggered by the glucose level, it would enable a
versatile, feedback control system for diabetics. Therefore, it was sought to
fabricate glucose-sensitive AVT particles capable of being cleaved by elevated
pulmonary glucose. A concanavalin A (ConA) based linkage was implemented
between liposomes in the AVT particles. Liposomes with glycosyl groups at the
distal ends of PEG tethers were rapidly agglomerated by ConA. Upon exposure
of the agglomerates to free glucose, a reduction in size was observed due to
cleavage of the links resulting from the preferential binding of ConA to free
glucose. It was envisaged that this cleavage would result in triggered release of
insulin from these AVT particles. Since pulmonary glucose levels are virtually
zero in normal humans, but are elevated in diabetics the glucose-ConA system
appeared to be a suitable candidate for auto-modulated release of insulin. The
AVT particles made from this construct were tested in rats which showed
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controlled and auto-modulated release of insulin [57]. Though this construct has
limitations due to toxicity concerns of ConA, the underlying hypothesis that
auto-modulation is possible was demonstrated. Currently, substitutes for ConA
that are acceptable for use in vivo, like boronates, are being investigated.
To treat local lung diseases, the particle could target a specific site of the
lungs by appropriate adjustment of the aerodynamic properties. Additionally, it
could “sense” an onset of the problem and trigger the release of additional drug.
For example, the first line of asthma therapy is based on inhaled corticosteroids
and β2 agonist catecholamines acting as bronchodilators. Once the particle
carrying the bronchodilator deposits in the lungs, it would continuously release
small amounts of its drug content, thus providing prophylaxis. However, once
the particle “senses” (where the AVT particle can be made sensitive to elevated
levels of cytokines, chemokines, etc.) an asthma attack, extra amounts of the
bronchodilator and an anti-inflammatory drug (e.g. albuterol) could be released
to control the condition.
It is envisioned that this technology can be used with a variety of drugs,
providing significant control over a disease condition and also improve patient
compliance.

135

Bibliography
1. O’Callaghan C, Nerbrink O, Vidgren M. The History of Inhaled Drug
Therapy. Drug delivery to the Lung, Lung Biology in Health and Disease,
vol. 162, Marcel Dekker, Inc. NY, 2002, pp 1-3.
2. Adjei AL, Gupta PK. Inhalation delivery of therapeutic peptides and
proteins, Lung Biology in Health and Disease, vol. 107, Marcel Dekker
Inc., New York, 1997.
3. Mckone T, Huey B, Downing E, Duffy L. Strategies to protect the health of
deployed U.S. forces: Detecting, characterizing, and documenting
exposures, editors; Division of Military Science and Technology and
Board on Environmental Studies and Toxicology, National Research
Council (Ed.), 2000.
4. Wigley FM, Londono JH, Wood JH. Insulin across respiratory mucosa by
aerosol delivery, Diabetes 20 (1971), pp 552-556.
5. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and
pharmacodynamics of inhaled insulin, Clin. Pharma. 43 (2004), pp 781801.
6. Edwards D, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew M,
Mintzes J, Deaver D, Lotan N, Langer R. Large porous particles for
pulmonary drug delivery, Science 276 , 1997, pp 1868-1871.

136

7. Bhavane R, Karathanasis E, Annapragada AV. Agglomerated vesicle
technology: A new class of particles for controlled and modulated
pulmonary drug delivery, Jour. of Controlled Release 93, 2003, pp 15– 28.
8. Karathanasis E, Ayyagari AL, Bhavane R, Bellamkonda RV, Annapragada
AV. Preparation of ‘in vivo’ cleavable agglomerated liposomes suitable for
modulated pulmonary drug delivery, Jour. of Controlled Release 103,
2005, pp 159-175.
9. Karathanasis E, Bhavane R, and Annapragada AV. Triggered Release of
Inhaled Insulin from the Agglomerated Vesicles: Pharmacodynamic
Studies in Rats. Jour. of Controlled Release 113 (2), 2006, pp 117-127.
10. Stocks J. Developmental physiology and methodology. Am. Jour. Resp.
Crit. Care Med. 151, 1995, S15-S17.
11. Martin TR, Feldman HA, Fredberg JJ, Castile RG, Mead J, Wohl MEB.
Relationship between maximal expiratory flows and lung volumes in
growing humans, Jour. Appl. Physiol. 65, 1988, pp 822-828.
12. Gray H. Anatomy of the human body, 20th edition, Philadelphia: Lea &
Febiger, 1918, New York: Bartleby.com, 2000.
13. Weibel ER. Morphometry of the human lung, New York, Academic Press
1963.
14. Thurlbeck WM. The internal surface area of nonemphysematous lungs,
Am. Rev. Respir. Dis. 95, 1967, pp 765-770.

137

15. Stone KC, Mercer RR, Gehr P, Stockstill B, Crapo JD. Allometric
relationships of cell numbers and size in the mammalian lung, Am.
Respir. Cell Mol. Biol. 6, 1992, pp 235-243.
16. Patton JS. Mechanisms of macromolecule absorption by the lungs,
Advanced Drug Delivery Reviews 19, 1996, pp 3-36.
17. Edwards DA, Dunbar C. Bioengineering of therapeutic aerosols, Annual
Reviews of Biomedical Engineering 4, 2002, pp 93-107.
18. Annapragada A, Swanson P, Muzzio F. Biophysics of inhaled drug
particles, Inhalation delivery of therapeutic peptides and proteins: Adjei
AL, Gupta PK, editors, Marcel Dekker Inc., New York, 1997, pp 27-58.
19. Davis SS. Delivery of peptide and non-peptide drugs through the
respiratory tract, PSTT 2, 1999, pp 450-456.
20. Zalipsky S. Synthesis of an end-group functionalized polyethylene glycollipid

conjugate

for

preparation

of

polymer-grafted

liposomes,

Bioconjugate chemistry 4, 1993, pp 296-299.
21. Hermanson G. Bioconjugate techniques, Academic press, New York, 1996.
22. Brady R, Ball R. Fractal growth of copper electrodeposits, Nature 309,
1984, pp 225-229.
23. Feder F, Jossang T, Rosenqvist E. Scaling behavior and cluster fractal
dimension determined by light scattering from aggregating proteins,
Physical Review Letters 53, 1984, pp 1403-1406.

138

24. Meakin P. Computer simulation of growth and aggregation processes of
On Growth and Form: Fractal and Non-Fractal Patterns in Physics, Stanley
E and Ostrowsky N, editors, Nijhoff, Boston, 1986, pp 111-135.
25. Mandelbrot BB, Vespignani A, Kaufman H. Crosscut analysis of large
radial DLA: departures from self-similarity and lacunarity effects,
Europhysics Letters 32, 1995, pp 199-204.
26. Kisak ET, Kennedy MT, Trommeshauser D, Zasadzinski JA. Self-limiting
aggregation by controlled ligand-receptor stoichiometry, Langmuir 16,
2000, pp 2825-2831.
27. Zalipsky S, Qazen M, Walker II J, Mullah N, Quinn Y, Huang S. New
detachable
lipopolymers

poly(ethylene

glycol)

regenerating

conjugates:

natural

Cysteine-cleavable

phospholipids,

diacyl

phosphatidylethanolamine, Bioconjugate Chemistry 10, 1999, pp 703-707
28. Lasic D, Martin F. Stealth Liposomes, CRC Press Inc, 1995.
29. Lasic D, Papahadjopoulos D. Medical applications of liposomes, Elsevier,
1998.
30. Lasic D, Liposomes from physics to applications, Elsevier, 1993.
31. Bridges P, Taylor K. An investigation of some of the factors influencing
the jet nebulization of liposomes, International Journal of Pharmaceutics
204, 2000, pp 69-79.
32. Miyajima K. Role of saccharides for the freeze-thawing and freeze-drying
of liposome, Advanced drug delivery reviews 24, 1997, pp 151-159.

139

33. Mitra R, Pezron I, Li Y, Mitra A. Enhanced pulmonary delivery of insulin
by lung lavage fluid and phospholipids, International journal of
pharmaceutics 217, 2001, pp 25-31.
34. Madden TD, Harrigan PR, Tai LCL, Bally MB, Mayer LD, Redelmeier TE,
Loughrey HC, Tilcock CPS, Reinish LW, and Cullis PR. The accumulation
of drugs within large unilamellar vesicles exhibiting a proton gradient: a
survey. Chem. Phys. Lipids 53, 1990, pp 37–46.
35. Hope MJ and Wong KF. Liposomal formulation of Ciprofloxacin, Shek
PN, editors, Liposomes in biomedical applications. Harwood Academic
Publishers, Germany, 1995, pp 121–134.
36. Lasic DD, Ceh B, Stuart MCA, Guo L, Frederik PM, and Barenholz Y.
Transmembrane gradient driven phase transitions within vesicles: lessons
for drug delivery, Biochim. Biophys. Acta, 1239, 1995, pp 145–156.
37. Oh YK, Nix DE, and Straubinger RM. Formulation and efficacy of
liposome-encapsulated

antibiotics

for

therapy

of

intracellular

Mycobacterium avium infection. Antimicrob. Agents Chemother. 39, 1995,
pp 2104–2111.
38. Bhavane R. Agglomerated particles for pulmonary drug delivery. MS
Thesis, Cleveland State University, OH, 2002.
39. Herb C, Berger E, Chang K, Morrison I, and Grabowski E. Using quasielastic

light

scattering

to

study

140

particle

size

distributions

in

submicrometer emulsion systems, in: Particle size distribution, Provder T,
editor, ACS symposium series 332, 1985, pp 89-104.
40. Gulari E, Annapragada A, Jawad B. Determination of particle size
distribution using light-scattering techniques, in: Particle size distribution,
Provder T, editor, ACS symposium series 332, 1985, pp 133-143.
41. Annapragada A, Adjei AL. An analysis of the Fraunhofer Diffraction
method for particle size distribution analysis and its application to
aerosolized sprays, International Journal of Pharmaceutics 127, 1996, pp
219-227.
42. Finlay WH and Stapleton KW. Undersizing of droplets from a vented
nebulizer caused by aerosol heating during transit through an Andersen
impactor, J. Aerosol Sci., vol. 30, no. 1, 1999, pp 105-109.
43. Desai TR, Hancock REW, and Finlay WH. A facile method of delivery of
liposomes by nebulization, Jour. Of Controlled Release, 84, 2002, pp 69-78.
44. Colino CI, Turino AG, Navarro AS, and Lanao JM. A comparative study
of Ofloxacin and Ciprofloxacin erythrocyte distribution, Biopharm. Drug
Dispos. 19, 1998, pp 71– 77.
45. Barret PHR, Bell BM, Cobelli C, Golde H, Schumitzki A, Vicini P, and
Foster DM. SAAM II: Simulation, analysis, and modeling software for
tracer and pharmacokinetic studies, Metabolism 47, 1998, pp 484-492.
46. Heatherington

AC,

Vicini

pharmacokinetic/pharmacodynamic

141

P,

and

comparison

Golde
of

SAAM

H.

A

II

and

PC/WinNonlin modeling software, Journal of Pharmaceutical Sciences 87,
1998, pp 1255-1263.
47. Bell BM, Burke JV, and Schumitzky A. A relative weighting method for
estimating parameters and variances in multiple data sets, Computational
Statistics & Data Analysis 22, 1996, pp 119-135.
48. Matot I, Manevich Y, Al-Mehdi A, Song C, and Fisher A. Fluorescence
imaging of lipid peroxidation in isolated rat lungs during nonhypoxic
lung ischemia. Free Radical Biology & Medicine, vol. 34, no. 6, 2003, pp
785–790.
49. Sood S, Characterization of liposome manufacturing using extrusion,
Master’s thesis, 1999.
50. Wong JY, Kuhl TL, Israelachvili JN, Mullah N, and Zalipsky S. Direct
measurement of a tethered ligand-receptor interaction potential, Science
275, 1997, pp 820-822.
51. Krill SL, Harn J, Hahn KR, and Gupta SL. Activity loss on room
temperature storage of Survanta, a bovine lung extract based surfactant,
International Journal of Pharmaceutics 132, 1996, pp 89-94.
52. Webb MS, Boman NL, Wiseman DJ, Saxon D, Sutton K, Wong KF, Logan
P, and Hope MJ. Antibacterial Efficacy against an in vivo Salmonella
typhimurium infection model and pharmacokinetics of a liposomal
Ciprofloxacin formulation. Antimicrobial Agents and Chemotherapy, vol.
42, no. 1, 1998, pp 45–52.

142

53. Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, and Schofield LN.
Liposome delivery of Ciprofloxacin against intracellular Francisella
tularensis infection, Journal of Controlled Release 92, 2003, pp 265– 273.
54. Kim C, Chung H, Lee M, Choi L, and Kim M. Development of dried
liposomes containing b-galactosidase for the digestion of lactose in milk,
International Journal of Pharmaceutics 183, 1999, pp 185–193.
55. Hincha DK and Crowe JH. Trehalose increases freeze–thaw damage in
liposomes containing chloroplast glycolipids, Cryobiology 36, 1998, pp
245–249.
56. Quintilio W, Sato RA, Sant’Anna OA, Esteves MI, Sesso A, de Araujo PS,
and Bueno da Costa MH. Large unilamellar vesicles as trehalose-stabilized
vehicles for vaccines: storage time and in vivo studies, Journal of
Controlled Release 67, 2000, pp 409–413.
57. Karathanasis E. Triggered and autoregulated pulmonary delivery of
insulin, PhD thesis, University of Houston, TX, 2005.

143

